

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

^{Pr} **Auro-Ritonavir**

Ritonavir Tablets

100 mg

House standard

Human Immunodeficiency Virus (HIV) Protease Inhibitor (ATC Code: J05AE03)

Auro Pharma Inc.

3700 Steeles Avenue West, Suite # 402
Woodbridge, Ontario, L4L 8K8
CANADA

Date of Initial Authorization:
December 22, 2021.

Submission Control Number: 216126

RECENT MAJOR LABEL CHANGES

None at time of authorization.

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES2

TABLE OF CONTENTS.....2

PART I: HEALTH PROFESSIONAL INFORMATION 4

1 INDICATIONS 4

 1.1 Pediatrics..... 4

 1.2 Geriatrics..... 4

2 CONTRAINDICATIONS 4

3 SERIOUS WARNINGS AND PRECAUTIONS BOX 7

4 DOSAGE AND ADMINISTRATION 7

 4.1 Dosing Considerations 7

 4.2 Recommended Dose and Dosage Adjustment..... 8

 4.3 Reconstitution..... 8

 4.4 Administration..... 8

 4.5 Missed Dose..... 8

5 OVERDOSAGE 8

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING 9

7 WARNINGS AND PRECAUTIONS 10

 7.1 Special Populations 14

 7.1.1 Pregnant Women..... 14

 7.1.2 Breast-feeding 15

 7.1.3 Pediatrics..... 15

 7.1.4 Geriatrics..... 15

8 ADVERSE REACTIONS 16

 8.1 Adverse Reaction Overview..... 16

 8.2 Clinical Trial Adverse Reactions 16

 8.2.1 Clinical Trial Adverse Reactions-Pediatrics..... 20

 8.3 Less Common Clinical Trial Adverse Reactions 20

 8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data 21

 8.5 Post-Market Adverse Reactions 23

9 DRUG INTERACTIONS.....	24
9.1 Serious Drug Interactions	24
9.2 Drug Interactions Overview.....	24
9.3 Drug-Behavioural Interactions.....	25
9.4 Drug-Drug Interactions.....	25
9.5 Drug-Food Interactions	42
9.6 Drug-Herb Interactions	42
9.7 Drug-Laboratory Test Interactions	42
10 ACTION AND CLINICAL PHARMACOLOGY	43
10.1 Mechanism of Action.....	43
10.2 Pharmacodynamics	43
10.3 Pharmacokinetics	43
11 STORAGE, STABILITY AND DISPOSAL.....	46
12 SPECIAL HANDLING INSTRUCTIONS.....	46
PART II: SCIENTIFIC INFORMATION	47
13 PHARMACEUTICAL INFORMATION	47
14 CLINICAL TRIALS.....	48
14.1 Trial Design and Study Demographics.....	48
14.2 Study Results.....	49
14.3 Comparative Bioavailability Studies.....	50
15 MICROBIOLOGY	52
16 NON-CLINICAL TOXICOLOGY.....	53
17 SUPPORTING PRODUCT MONOGRAPHS.....	58
PATIENT MEDICATION INFORMATION	59

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

Auro-Ritonavir (ritonavir) is indicated in combination with other antiretroviral agents for the treatment of HIV infection when therapy is warranted.

1.1 Pediatrics

Pediatrics (2 to 16 years of age): Ritonavir concentrations obtained after 350 to 400 mg/m² twice daily in pediatric patients were comparable to those obtained in adults receiving 600 mg (approximately 330 mg/m²) twice daily (see **10.3 Pharmacokinetics**). The safety and effectiveness of Auro-Ritonavir in pediatric patients below the age of 2 years have not been established.

1.2 Geriatrics

Geriatrics (> 65 years of age): Clinical studies of ritonavir did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects. In general, appropriate caution should be exercised in the administration and monitoring of Auro-Ritonavir in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

2 CONTRAINDICATIONS

When Auro-Ritonavir is used as a pharmacokinetic enhancer with other protease inhibitors, see the full prescribing information of that protease inhibitor including contraindication information.

Auro-Ritonavir is contraindicated in patients with known hypersensitivity [e.g., toxic epidermal necrosis (TEN) or Stevens Johnson syndrome (SJS)] to ritonavir or any of its ingredients (see **6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING**).

Co-administration of Auro-Ritonavir is contraindicated with the drugs listed in **Table 1** (see also **9.1 Serious Drug Interactions**) because competition for primarily CYP3A by ritonavir could result in inhibition of the metabolism of these drugs and create the potential for serious and/or life-threatening reactions, such as cardiac arrhythmias, prolonged or increased sedation, and respiratory depression. Voriconazole and St. John's Wort are exceptions in that co-administration of ritonavir and voriconazole results in a significant reduction in plasma concentrations of voriconazole and possible loss of effect, and co-administration of ritonavir with St. John's Wort may lead to loss of virologic response and possible resistance to ritonavir.

Table 1 - Drugs that are contraindicated with Auro-Ritonavir

Drug Class	Drugs Within Class that are Contraindicated with ritonavir	Clinical Comment
Alpha1-Adrenorecept or Antagonist	alfuzosin	Potential for serious reactions, such as hypotension (see Table 6).
Antianginal	ranolazine	Potential for serious and/or life-threatening reactions.
Antiarrhythmics	amiodarone, bepridil ^a , dronedarone, flecainide, propafenone, quinidine	Potential for serious and/or life-threatening reactions, such as cardiac arrhythmias.
Antibiotic	fusidic acid	Potential of increased fusidic acid-associated adverse events, such as hepatitis or bone marrow suppression.
Anticancer	apalutamide	Apalutamide is a moderate to strong CYP3A4 inducer and this may lead to a decreased exposure of ritonavir and potential loss of virologic response. In addition, exposure of apalutamide may increase with co-administration of ritonavir that may lead to serious adverse events including seizure and fracture.
	neratinib	Potential for serious and/or life-threatening reactions including hepatotoxicity.
	venetoclax ^d	Concomitant use of strong CYP3A inhibitors, such as ritonavir, and venetoclax may increase the risk of tumor lysis syndrome at the dose initiation and during the ramp-up phase.
Anticoagulant	rivaroxaban	Potential of increased rivaroxaban plasma concentrations which may lead to risk of increased bleeding.
Antifungal	voriconazole	Significant reduction in voriconazole plasma concentrations and possible loss of effect (see Table 7).
Antigout	colchicine	Potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment (see Table 6).
Antihistamines	astemizole ^a , terfenadine ^a	Potential for serious and/or life-threatening reactions, such as cardiac arrhythmias.

Drug Class	Drugs Within Class that are Contraindicated with ritonavir	Clinical Comment
Antipsychotics	lurasidone pimozide	Potential for serious and/or life-threatening reactions. Potential for serious and/or life-threatening reactions, such as cardiac arrhythmias.
Ergot Derivatives	dihydroergotamine, ergonovine, ergotamine ^a , methylergonovine ^a	Potential for serious and/or life-threatening reactions, such as acute ergot toxicity characterized by vasospasm and tissue ischemia.
GI Motility Agent	cisapride ^a	Potential for serious and/or life-threatening reactions, such as cardiac arrhythmias.
Herbal Products	St. John's wort (<i>Hypericum perforatum</i>)	May lead to loss of virologic response and possible resistance to ritonavir or to the class of protease inhibitors.
Lipid-modifying agents		
HMG-CoA Reductase Inhibitors	lovastatin, simvastatin	Potential for serious reactions, such as risk of myopathy including rhabdomyolysis.
Microsomal triglyceride transfer protein (MTTP) Inhibitor	lomitapide	Potential for serious reactions, such as hepatotoxicity.
Long Acting Beta-Adrenoceptor	salmeterol	May result in potential increased risk of cardiovascular adverse events associated with salmeterol.
PDE5 Inhibitors	sildenafil ^b , only when used for the treatment of pulmonary arterial hypertension (PAH) vardenafil, when used for the treatment of erectile dysfunction or PAH	Potential increase in PDE5 inhibitor associated adverse reactions including hypotension, syncope, visual changes, and prolonged erection. Potential increase in PDE5 inhibitor associated adverse reactions including hypotension, syncope, visual changes, and prolonged erection.

Drug Class	Drugs Within Class that are Contraindicated with ritonavir	Clinical Comment
Sedative/Hypnotics	orally administered midazolam ^C , triazolam	Potential for serious and/or life-threatening reactions, such as prolonged or increased sedation or respiratory depression.

- a. Product no longer marketed in Canada.
- b. See **7 WARNINGS AND PRECAUTIONS** and **6 DRUG INTERACTIONS** for co-administration of sildenafil in patients with erectile dysfunction.
- c. See **Table 6** for parenterally administered midazolam. Oral formulation of midazolam is not marketed in Canada.
- d. See **Table 6** for coadministration of the maintenance dose of venetoclax.

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions
<ul style="list-style-type: none"> ● Pancreatitis should be considered if clinical symptoms (nausea, vomiting, abdominal pain) or abnormalities in laboratory values (such as increased serum lipase or amylase values) suggestive of pancreatitis should occur. Patients who exhibit these signs or symptoms should be evaluated and Auro-Ritonavir therapy should be discontinued if a diagnosis of pancreatitis is made (see 7 WARNINGS AND PRECAUTIONS). ● Co-administration of ritonavir with certain non-sedating antihistamines, sedative hypnotics, or antiarrhythmics may result in potentially serious and/or life-threatening adverse events due to possible effects of ritonavir on the hepatic metabolism of certain drugs (see 2 CONTRAINDICATIONS and 9 DRUG INTERACTIONS). ● See 9.1 Serious Drug Interactions

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

Patients should be aware that frequently observed adverse events, such as mild to moderate gastrointestinal disturbances and paresthesias, may diminish as therapy is continued. In addition, patients initiating combination regimens with ritonavir and other antiretroviral agents may improve gastrointestinal tolerance by initiating Auro-Ritonavir alone and subsequently adding the other antiretroviral agents before completing 2 weeks of Auro-Ritonavir monotherapy. The long-term effects of dose escalation on efficacy have not been established.

Dose reduction of Auro-Ritonavir is necessary when used with other protease inhibitors: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir.

When Auro-Ritonavir is used as a pharmacokinetic enhancer with other protease inhibitors, see the full prescribing information and clinical study information of that protease inhibitor.

4.2 Recommended Dose and Dosage Adjustment

Adult Patients

The recommended dose of Auro-Ritonavir is 600 mg (6 tablets) twice daily orally and should be taken with a meal.

Auro-Ritonavir tablets should be swallowed whole with water and not chewed, broken, or crushed.

Some patients experience nausea upon initiation of 600 mg twice daily dosing. Use of a dose titration schedule may help to reduce treatment-emergent adverse events while maintaining appropriate ritonavir plasma levels. Auro-Ritonavir should be started at no less than 300 mg twice daily and increased by 100 mg twice daily increments up to 600 mg twice daily. The titration period should not exceed 14 days.

Pediatric Patients (2 to 16 years of age)

Auro-Ritonavir should be used in combination with other antiretroviral agents.

4.3 Reconstitution

Not applicable.

4.4 Administration

Auro-Ritonavir is administered orally.

4.5 Missed Dose

If a dose of this medication has been missed, it should be taken as soon as possible. However, if it is almost time for the next dose, skip the missed dose and go back to the regular dosing schedule. Do not double doses.

5 OVERDOSAGE

Acute Overdosage

Human Overdose Experience

Human experience of acute overdose with ritonavir is limited. One patient in clinical trials took ritonavir 1500 mg/day for 2 days. The patient reported paresthesias which resolved after the dose was decreased.

A post-marketing case of renal failure with eosinophilia has been reported with ritonavir overdose.

Management of Overdosage

Administration of activated charcoal may be used to aid in removal of unabsorbed drug. Treatment of overdose with Auro-Ritonavir consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with Auro-Ritonavir. Since ritonavir is extensively metabolized by the liver and is highly protein-bound, dialysis is unlikely to be beneficial in significant removal of the drug.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 2 - Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form/Strength/Composition	Non-medicinal Ingredients
Oral	Tablets / 100 mg	<p>The film coat, Aquarius Prime BAP 118010 White contains: Hypromellose 2910, Titanium Dioxide, Talc, Polyethylene glycol and Polysorbate.</p> <p>The tablet core contains: Calcium Hydrogen Phosphate Anhydrous, Calcium Hydrogen Phosphate Dihydrate, Copovidone, Maize starch, Mannitol, Microcrystalline Cellulose, Silicified Microcrystalline Cellulose (Prosolv SMCC 50), Silicified Microcrystalline Cellulose (Prosolv SMCC 90), Powdered Cellulose, Sodium Stearyl Fumarate and Sorbitan Laurate.</p>

Auro-Ritonavir tablets are White to off-white, film-coated, ovaloid tablets, debossed with '1' on one side and '100' on other side. Available in HDPE bottles of 30, 60 and 90 Tablets and Blister Pack of 8x10's

7 WARNINGS AND PRECAUTIONS

Please see **3 WARNINGS AND PRECAUTIONS BOX**

Drug-Drug Interactions

When Auro-Ritonavir is used as a pharmacokinetic enhancer with other protease inhibitors, see the full prescribing information of that protease inhibitor including Warning and Precautions.

Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) both in vitro and in vivo. Ritonavir also inhibits CYP2D6 in vitro, but to a lesser extent than CYP3A.

Initiation of Auro-Ritonavir, a CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving Auro-Ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. Initiation of medications that inhibit or induce CYP3A may increase or decrease concentrations of Auro-Ritonavir, respectively. These interactions may lead to:

- Clinically significant adverse reactions, potentially leading to severe, life-threatening, or fatal events from greater exposures of concomitant medications.
- Clinically significant adverse reactions from greater exposures of ritonavir.
- Loss of therapeutic effect of ritonavir and possible development of resistance.

Due to inhibition of CYP3A by ritonavir, co-administration of ritonavir with quetiapine may result in increased quetiapine concentrations. Serious and life-threatening quetiapine-related adverse reactions have been reported with CYP3A inhibitors. Auro-Ritonavir should not be used in combination with quetiapine. Monitoring and dose reduction may be required if necessary (see **Table 6**).

See **Table 6** for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations (see **9 DRUG INTERACTIONS**). Consider the potential for drug interactions prior to and during Auro-Ritonavir therapy; review concomitant medications during Auro-Ritonavir therapy, and monitor for the adverse reactions associated with the concomitant medications (see **2 CONTRAINDICATIONS** and **9 DRUG INTERACTIONS**).

Allergic Reactions

Allergic reactions including urticaria, skin eruptions, bronchospasm, and angioedema have been reported. Rare cases of anaphylaxis, toxic epidermal necrosis (TEN) and Stevens-Johnson syndrome (SJS) have also been reported. Discontinue treatment if these reactions occur.

Organ Targets for Toxicity

Toxicological studies in laboratory animals identified various organs as targets for toxicity at drug exposures below or approaching those achieved in patients participating in clinical trials with ritonavir. Because no safety margin or a small safety margin has been demonstrated in long-term studies, these organs should be assessed periodically or if clinical signs and symptoms occur during therapy (see **16 NON-CLINICAL TOXICOLOGY**).

Carcinogenesis and Mutagenesis

For a brief discussion of pre-clinical carcinogenicity data, see **16 NON-CLINICAL TOXICOLOGY**. No evidence of mutagenic or clastogenic activity have been reported in a battery of in vitro and in vivo assays.

Cardiovascular

PR Interval Prolongation

Ritonavir has been shown to cause asymptomatic prolongation of the PR interval in some patients.

Post-marketing reports of second or third degree atrioventricular block have been reported in patients with underlying structural heart disease and pre-existing conduction system abnormalities, ischemic heart disease, cardiomyopathies, as these patients may be at increased risk of cardiac conduction abnormalities, or in patients receiving drugs known to prolong the PR interval (such as calcium channel blockers, beta-adrenergic blockers, digoxin, verapamil or atazanavir).

Co-administration of ritonavir with these drugs should be undertaken with caution, particularly with drugs metabolized by CYP3A4 (see **10.2 Pharmacodynamics**). Clinical monitoring is recommended (see **9 DRUG INTERACTIONS**).

Endocrine and Metabolism

Diabetes Mellitus/Hyperglycemia

Levels of blood glucose may increase during antiretroviral therapy. Such changes may in part be linked to the treatment per se (e.g., protease inhibitors), and in part to disease control and life style. New onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus and hyperglycemia have been reported during post-marketing surveillance in HIV-infected patients receiving protease inhibitor therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. In some cases diabetic ketoacidosis has occurred. In those patients who discontinued protease inhibitor therapy, hyperglycemia persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and a causal

relationship between protease inhibitor therapy and these events has not been established. For monitoring of blood glucose, reference is made to established HIV treatment guidelines. Glucose elevations should be managed as clinically appropriate (see **7 WARNINGS AND PRECAUTIONS**).

Lipid Disorders

Levels of blood lipids may increase during antiretroviral therapy. Such changes may in part be linked to the treatment per se (e.g., protease inhibitors), and in part to disease control and life style (see **Table 5**).

Triglycerides and cholesterol testing should be performed prior to initiating ritonavir therapy and at periodic intervals during therapy (see **7 WARNINGS AND PRECAUTIONS**). For monitoring of blood lipids, reference is made to established HIV treatment guidelines. Lipid disorders should be managed as clinically appropriate.

Hematologic

There have been reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis, in patients with hemophilia type A and type B treated with protease inhibitors. In some patients, additional Factor VIII was given. In more than half of the reported cases, treatment with protease inhibitors was continued or re-introduced. There is no proven relationship between protease inhibitors and such bleeding; however, the frequency of bleeding episodes should be closely monitored in patients on ritonavir.

Hepatic/Biliary/Pancreatic

Impaired Hepatic Function

Ritonavir is principally metabolized by the liver. Pre-clinical studies have identified the liver as a toxicity target (see **16 NON-CLINICAL TOXICOLOGY**). Therefore, appropriate tests should be performed at treatment initiation and at periodic intervals to assess hepatic function.

Caution should be exercised when administering Auro-Ritonavir to patients with impaired hepatic function.

Hepatic Reactions

Hepatic transaminase elevations exceeding 5 times the upper limit of normal, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir alone or in combination with other antiretroviral drugs (see **Table 5**). There may be an increased risk for transaminase elevations in patients with underlying hepatitis B or C. Therefore, caution should be exercised when administering Auro-Ritonavir to patients with pre-existing liver disease, liver enzyme abnormalities, or hepatitis. Liver enzyme elevations should be monitored as clinically appropriate (see **7 WARNINGS AND PRECAUTIONS**).

There have been post-marketing reports of hepatic dysfunction, including some fatalities. These have generally occurred in patients taking multiple concomitant medications and/or with advanced AIDS.

Pancreatitis

Pancreatitis has been observed in patients receiving ritonavir therapy, including those who developed hypertriglyceridemia. In some cases fatalities have been observed. Patients with advanced HIV disease may be at increased risk of elevated triglycerides and pancreatitis.

Pancreatitis should be considered if clinical symptoms (nausea, vomiting, abdominal pain) or abnormalities in laboratory values (such as increased serum lipase or amylase values) suggestive of pancreatitis should occur. Patients who exhibit these signs or symptoms should be evaluated and Auro-Ritonavir therapy should be discontinued if a diagnosis of pancreatitis is made.

Immune

Immune Reconstitution Inflammatory Syndrome

Immune reconstitution inflammatory syndrome has been reported in HIV-infected patients treated with combination antiretroviral therapy, including ritonavir. During the initial phase of treatment, patients responding to antiretroviral therapy may develop an inflammatory response to indolent or residual opportunistic infections (such as *Mycobacterium avium* infection, cytomegalovirus, *Pneumocystis jirovecii* pneumonia, or tuberculosis), which may necessitate further evaluation and treatment.

Autoimmune disorders (such as Graves' disease, polymyositis, Guillain-Barré syndrome, and autoimmune hepatitis) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.

Monitoring and Laboratory Tests

Ritonavir has been associated with elevations in cholesterol, triglycerides, SGOT (AST), SGPT (ALT), GGT, CK, and uric acid. Appropriate laboratory testing should be performed prior to initiating ritonavir therapy and at periodic intervals or if any clinical signs or symptoms occur during therapy. For monitoring of liver enzymes, blood lipids, and glucose refer to established HIV treatment guidelines. For comprehensive information concerning laboratory test alterations associated with other antiretroviral agents, physicians should refer to the complete product information for each of these drugs.

Neurologic

Central nervous system (CNS) penetration of ritonavir has not been established.

Sensitivity/Resistance

Resistance

Mutations associated with the HIV viral protease in isolates obtained from 41 patients appeared to occur in a stepwise and ordered fashion.

The clinical relevance of phenotypic and genotypic changes associated with ritonavir therapy has not been established (see **15 MICROBIOLOGY**).

Cross-Resistance

Serial HIV isolates obtained from 6 patients during ritonavir therapy showed a decrease in ritonavir susceptibility in vitro to indinavir (8-fold), nelfinavir (12- to 14-fold), and none to amprenavir. One zidovudine (ZDV)-resistant HIV isolate tested in vitro retained full susceptibility to ritonavir (see **15 MICROBIOLOGY**).

7.1 Special Populations

7.1.1 Pregnant Women

There are no adequate and well-controlled studies in pregnant women. Prospective pregnancy data from the Antiretroviral Pregnancy Registry (APR) are not sufficient to adequately assess the risk of birth defects or miscarriage. Based on approximately 6100 live births following exposure to ritonavir-containing regimens (including over 2800 live births exposed in the first trimester and over 3200 live births exposed in the second and third trimesters) in the APR, there was no difference in the rate of overall birth defects for ritonavir compared with the background birth defect rate of 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). The prevalence of birth defects in live births was 2.3% (95% CI: 1.7%-2.9%) following first-trimester exposure to ritonavir-containing regimens and 2.9% (95% CI: 2.3%-3.5%) following second and third trimester exposure to ritonavir-containing regimens. The prevalence of birth defects after any trimester exposure to ritonavir is comparable to the prevalence observed in the general population.

Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

In rat fertility studies, hepatic toxicity precluded drug exposures equal to those achieved with the proposed human therapeutic dose. No effects on fertility in rats were produced at drug exposures approximately 40% (male) and 60% (female) of that achieved with the proposed human therapeutic dose.

No treatment-related malformations were observed when ritonavir was administered to pregnant rats or rabbits. Developmental toxicity observed in rats (early resorptions, decreased fetal body weight and ossification delays and developmental variations) occurred at a maternally toxic dosage at an exposure equivalent to approximately 30% of that achieved with the proposed therapeutic dose. A slight increase in the incidence of cryptorchidism was also noted in rats at an exposure approximately 22% of that achieved with the proposed therapeutic dose.

Developmental toxicity observed in rabbits (resorptions, decreased litter size and decreased fetal weights) also occurred at a maternally toxic dosage equivalent to 1.8 times the proposed therapeutic dose based on a body surface area conversion factor.

Antiretroviral Pregnancy Registry

To monitor maternal-fetal outcomes of pregnant women exposed to Auro-Ritonavir, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.

7.1.2 Breast-feeding

HIV-infected mothers should not breast-feed their infants to avoid risking postnatal transmission of HIV. Limited published data reports that ritonavir is present in human milk. There is no information on the effects of ritonavir on the breast-fed infant or the effects of the drug on milk production. Because of the potential for (1) HIV transmission (in HIV-negative infants), (2) developing viral resistance (in HIV-positive infants) and (3) serious adverse reactions in a breast-fed infant, instruct mothers **not to breast-feed if they are receiving Auro-Ritonavir.**

7.1.3 Pediatrics

Pediatrics (2 to 16 years of age): The safety and effectiveness of ritonavir in pediatric patients below the age of 2 years have not been established. Although the database in HIV-infected patients age 2 to 16 years is much smaller, the adverse event profile seen during a clinical trial and post-marketing experience was similar to that observed for adult patients.

7.1.4 Geriatrics

Geriatrics (> 65 years of age): Clinical studies of ritonavir did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects. In general, appropriate caution should be exercised in the administration and monitoring of ritonavir in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

When ritonavir is used as a pharmacokinetic enhancer with other protease inhibitors, see the full prescribing information of that protease inhibitor including Adverse Reactions.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful for identifying and approximating rates of adverse drug reactions in real-world use.

Adult Patients

The safety of ritonavir alone and in combination with nucleoside reverse transcriptase inhibitors was studied in 1270 adult patients.

Table 3 lists treatment-emergent adverse events (at least possibly related and of at least moderate intensity) that occurred in 2% or greater of adult patients receiving ritonavir alone or in combination with nucleoside reverse transcriptase inhibitors in Study M94-247 or Study M94-245 and in combination with saquinavir in Study M94-462. In that study, 141 protease inhibitor-naïve, HIV-infected patients with mean baseline CD4 of 300 cells/microliter were randomized to 1 of 4 regimens of ritonavir + saquinavir, including ritonavir 400 mg twice daily + saquinavir 400 mg twice daily. Overall, the most frequently reported adverse drug reactions among patients receiving ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal and neurological disturbances including diarrhea, nausea, vomiting, anorexia, abdominal pain (upper and lower), and neurological disturbances (including paresthesia and oral paresthesia), and fatigue/asthenia. Similar adverse event profiles were reported in adult patients receiving ritonavir in other trials.

Table 3. Percentage of Patients with Treatment-Emergent Adverse Events^a of Moderate or Severe Intensity Occurring in \geq 2% of Adult Patients Receiving Ritonavir

Adverse Events	Study M94-247 Advanced Patients ^b		Study M94-245 Naïve Patients ^c			Study M94-462 PI-Naïve Patients ^d
	Ritonavir (n = 541)	Placebo (n = 545)	Ritonavir + Zidovudine (n = 116)	Ritonavir (n = 117)	Zidovudine (n = 119)	Ritonavir ⁵ + Saquinavir (n = 141)
Body as a Whole						
Abdominal Pain	8.3	5.1	5.2	6.0	5.9	2.1
Asthenia	15.3	6.4	28.4	10.3	11.8	16.3
Fever	5.0	2.4	1.7	0.9	1.7	0.7
Headache	6.5	5.7	7.8	6.0	6.7	4.3

Adverse Events	Study M94-247 Advanced Patients ^b		Study M94-245 Naïve Patients ^c			Study M94-462 PI-Naïve Patients ^d
	Ritonavir (n = 541)	Placebo (n = 545)	Ritonavir + Zidovudine (n = 116)	Ritonavir (n = 117)	Zidovudine (n = 119)	Ritonavir ⁵ + Saquinavir (n = 141)
Malaise	0.7	0.2	5.2	1.7	3.4	2.8
Pain (unspecified)	2.2	1.8	0.9	1.7	0.8	4.3
Cardiovascular						
Syncope	0.6	0.0	0.9	1.7	0.8	2.1
Vasodilation	1.7	0.0	3.4	1.7	0.8	3.5
Digestive						
Anorexia	7.8	4.2	8.6	1.7	4.2	4.3
Constipation	0.2	0.4	3.4	0.0	0.8	1.4
Diarrhea	23.3	7.9	25.0	15.4	2.5	22.7
Dyspepsia	5.9	1.5	2.6	0.0	1.7	0.7
Fecal Incontinence	0.0	0.0	0.0	0.0	0.0	2.8
Flatulence	1.7	0.7	2.6	0.9	1.7	3.5
Liver Function Tests Abnormal	3.3	0.9	2.6	1.7	1.7	5.0
Local Throat Irritation	2.8	0.4	0.9	1.7	0.8	1.4
Nausea	29.8	8.4	46.6	25.6	26.1	18.4
Vomiting	17.4	4.4	23.3	13.7	12.6	7.1
Metabolic and Nutritional						
Creatinine Phosphokinase (CK) Increase	0.9	0.2	4.3	3.4	3.4	N/A
Hyperlipidemia	5.7	0.2	2.6	1.7	0.0	3.5
Weight Loss	2.4	1.7	0.0	0.0	0.0	0.0
Musculoskeletal						
Arthralgia	1.7	0.7	0.0	0.0	0.0	2.1
Myalgia	2.4	1.1	1.7	1.7	0.8	2.1
Nervous						
Anxiety	1.7	0.9	0.9	0.0	0.8	2.1
Circumoral Paresthesia	6.7	0.4	5.2	3.4	0.0	6.4
Confusion	0.6	0.6	0.0	0.9	0.0	2.1
Depression	1.7	0.7	1.7	1.7	2.5	7.1
Dizziness	3.9	1.1	5.2	2.6	3.4	8.5
Insomnia	2.0	1.8	3.4	2.6	0.8	2.8
Paresthesia	3.0	0.4	5.2	2.6	0.0	2.1
Peripheral Paresthesia	5.0	1.1	0.0	6.0	0.8	5.7
Somnolence	2.4	0.2	2.6	2.6	0.0	0.0
Thinking Abnormal	0.9	0.4	2.6	0.0	0.8	0.7
Respiratory						
Pharyngitis	0.4	0.4	0.9	2.6	0.0	1.4
Skin and Appendages						

Adverse Events	Study M94-247 Advanced Patients ^b		Study M94-245 Naïve Patients ^c			Study M94-462 PI-Naïve Patients ^d
	Ritonavir (n = 541)	Placebo (n = 545)	Ritonavir + Zidovudine (n = 116)	Ritonavir (n = 117)	Zidovudine (n = 119)	Ritonavir ⁵ + Saquinavir (n = 141)
Rash	3.5	1.5	0.9	0.0	0.8	0.7
Sweating	1.7	1.1	3.4	2.6	1.7	2.8
Special Senses						
Taste Perversion	7.0	2.2	17.2	11.1	8.4	5.0
Urogenital						
Nocturia	0.2	0.0	0.0	0.0	0.0	2.8
<p>a. Includes those adverse events at least possibly related to study drug or of unknown relationship and excludes concurrent HIV conditions.</p> <p>b. The median duration of treatment for patients randomized to regimens containing ritonavir in Study M94-247 was 9.4 months.</p> <p>c. The median duration of treatment for patients randomized to regimens containing ritonavir in Study M94-245 was 9.1 months.</p> <p>d. The median duration of treatment for patients in Study M94-462 was 48 weeks.</p> <p>e. The dose of ritonavir when co-administered with saquinavir was reduced to 400 mg twice daily.</p> <p>Definitions: N/A = Not available</p>						

Other Common Clinical Trial Adverse Drug Reactions

Table 4 includes other treatment-emergent adverse reactions (with possible or probable relationship to study drug) occurring in $\geq 1\%$ of adult patients receiving ritonavir derived from cumulative data from combined Phase 2 to 4 studies.

Table 4 - Treatment-Emergent Adverse Reactions (With Possible or Probable Relationship to Study Drug) Occurring in $\geq 1\%$ of Adult Patients Receiving ritonavir in Combined Phase 2 to 4 Studies (N = 1,755)

Adverse Reactions	n	%
Eye disorders		
Blurred vision	113	6.4
Gastrointestinal disorders		
Abdominal Pain (upper and lower)	464	26.4
Diarrhea including severe with electrolyte imbalance	1,192	67.9
Dyspepsia	201	11.5
Flatulence	142	8.1
Gastrointestinal hemorrhage	41	2.3

Gastroesophageal reflux disease (GERD)	19	1.1
Nausea	1,007	57.4
Vomiting	559	31.9
General disorders and administration site conditions		
Fatigue including asthenia	811	46.2
Hepatobiliary disorders		
Blood bilirubin increased (including jaundice)	25	1.4
Hepatitis (including increased AST, ALT, GGT)	153	8.7
Immune system disorders		
Hypersensitivity including urticaria and face edema	114	8.2
Metabolism and nutrition disorders		
Edema and peripheral edema	110	6.3
Gout	24	1.4
Hypercholesterolemia	52	3.0
Hypertriglyceridemia	158	9.0
Musculoskeletal and connective tissue disorders		
Arthralgia and back pain	326	18.6
Myopathy/creatine phosphokinase increased	66	3.8
Myalgia	156	8.9
Nervous system disorders		
Dizziness	274	15.6
Dysgeusia	285	16.2
Paresthesia (including oral paresthesia)	889	50.7
Peripheral neuropathy	178	10.1
Syncope	58	3.3
Psychiatric disorders		
Confusion	52	3.0
Disturbance in attention	44	2.5
Renal and urinary disorders		
Increased urination	74	4.2
Respiratory, thoracic and mediastinal disorders		
Coughing	380	21.7
Oropharyngeal Pain	279	15.9
Skin and subcutaneous tissue disorders		

Acne	67	3.8
Pruritus	214	12.2
Rash (includes erythematous and maculopapular)	475	27.1
Vascular disorders		
Flushing, feeling hot	232	13.2
Hypertension	58	3.3
Hypotension including orthostatic hypotension	30	1.7
Peripheral coldness	21	1.2

8.2.1 Clinical Trial Adverse Reactions-Pediatrics

The safety and pharmacokinetic profiles of ritonavir in pediatric patients below the age of 2 have not been studied. Although the database in HIV-infected patients age 2 to 16 years is much smaller, the adverse event profile seen during a clinical trial and post-marketing experience was similar to that observed for adult patients.

8.3 Less Common Clinical Trial Adverse Reactions

Adverse events occurring in less than 2% of adult patients receiving ritonavir in all Phase 2 /Phase 3 studies and considered at least possibly related or of unknown relationship to treatment and of at least moderate intensity are listed below by body system.

Body as a Whole:	abdomen enlarged, accidental injury, cachexia, chest pain, chills, facial pain, flu syndrome, hormone level altered, hypothermia, kidney pain, neck pain, neck rigidity, pelvic pain, photosensitivity reaction, and substernal chest pain
Cardiovascular System:	cardiovascular disorder, cerebral ischemia, cerebral venous thrombosis, hemorrhage, migraine, myocardial infarct, palpitation, peripheral vascular disorder, phlebitis, postural hypotension, tachycardia, and vasospasm
Digestive System:	abnormal stools, bloody diarrhea, cheilitis, cholangitis, cholestatic jaundice, colitis, dry mouth, dysphagia, eructation, esophageal ulcer, esophagitis, gastritis, gastroenteritis, gastrointestinal disorder, gingivitis, hepatic coma, hepatomegaly, hepatosplenomegaly, ileitis, ileus, liver damage, melena, mouth ulcer, oral moniliasis, pancreatitis, periodontal abscess, pseudomembranous colitis, rectal disorder, rectal hemorrhage, sialadenitis, stomatitis, tenesmus, thirst, tongue edema, and ulcerative colitis
Endocrine System:	adrenal cortex insufficiency and diabetes mellitus

Hemic and Lymphatic System:	acute myeloblastic leukemia, anemia, ecchymosis, leukopenia, lymphadenopathy, lymphocytosis, myeloproliferative disorder, and thrombocytopenia
Metabolism and Nutritional Disorders:	albuminuria, alcohol intolerance, avitaminosis, BUN increased, dehydration, enzymatic abnormality, glycosuria, and xanthomatosis
Musculoskeletal System:	arthritis, arthrosis, bone disorder, bone pain, extraocular palsy, joint disorder, leg cramps, muscle cramps, muscle weakness, myositis, and twitching
Nervous System Disorders:	abnormal dreams, abnormal gait, agitation, amnesia, aphasia, ataxia, coma, convulsion, dementia, depersonalization, diplopia, emotional lability, euphoria, grand mal convulsion, hallucinations, hyperesthesia, hyperkinesia, hypesthesia, incoordination, libido decreased, manic reaction, nervousness, neuralgia, neuropathy, paralysis, peripheral neuropathic pain, peripheral sensory neuropathy, personality disorder, sleep disorder, speech disorder, stupor, subdural hematoma, tremor, urinary retention, vertigo, and vestibular disorder
Respiratory System:	asthma, bronchitis, dyspnea, epistaxis, hiccup, hypoventilation, interstitial pneumonia, larynx edema, lung disorder, rhinitis, and sinusitis
Skin and appendages:	contact dermatitis, dry skin, eczema, erythema multiforme, exfoliative dermatitis, folliculitis, fungal dermatitis, furunculosis, molluscum contagiosum, onychomycosis, psoriasis, pustular rash, seborrhea, skin discoloration, skin disorder, skin hypertrophy, skin melanoma, and vesiculobullous rash
Special Senses:	abnormal electro-oculogram, abnormal electroretinogram, abnormal vision, amblyopia/blurred vision, blepharitis, conjunctivitis, ear pain, eye disorder, eye pain, hearing impairment, increased cerumen, iritis, parosmia, photophobia, taste loss, tinnitus, uveitis, visual field defect, and vitreous disorder
Urogenital System:	acute kidney failure, breast pain, cystitis, dysuria, hematuria, impotence, kidney calculus, kidney failure, kidney function abnormal, kidney pain, menorrhagia, penis disorder, polyuria, pyelonephritis, urethritis, urinary frequency, urinary tract infection, and vaginitis

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Clinical Trial Findings

Table 5 shows the percentage of adult patients who developed marked laboratory abnormalities.

Table 5 - Percentage of Adult Patients, by Study and Treatment Group, with Chemistry and Hematology Abnormalities Occurring in \geq 2% of Patients Receiving ritonavir

Variable	Limit	Study M94-247 Advanced Patients		Study M94-245 Naïve Patients			Study M94-462 PI-Naïve Patients
		Ritonavir (n = 541)	Placebo (n=545)	Ritonavir + ZDV (n = 116)	Ritonavir (n = 117)	ZDV (n=119)	Ritonavir + Saquinavir (n = 141)
Chemistry High							
Alkaline Phosphatase	> 550 IU/L	2.3	2.2	-	0.9	-	-
Cholesterol	> 6.22 mmol/L	36.5	8.0	30.7	44.8	9.3	65.2
CK	> 1000 IU/L	9.1	6.3	9.6	12.1	11.0	9.9
GGT	> 300 IU/L	19.6	11.3	1.8	5.2	1.7	9.2
Glucose	> 13.88 mmol/L	0.9	1.3	2.6	0.9	0.8	0.7
SGOT/AST	> 180 IU/L	6.4	7.0	5.3	9.5	2.5	7.8
SGPT/ALT	> 215 IU/L	8.5	4.4	5.3	7.8	3.4	9.2
Total Bilirubin	> 61.56 micromol/L	1.3	0.2	-	0.9	0.8	2.1
Triglycerides	> 9.04 mmol/L	33.6	9.4	9.6	17.2	3.4	23.4
Triglycerides	> 16.95 mmol/L	12.6	0.4	1.8	2.6	-	11.3
Triglycerides Fasting	> 16.95 mmol/L	9.9	0.3	1.5	1.3	-	-
Uric Acid	> 713.76 micromol/L	3.8	0.2	-	-	-	1.4
Chemistry Low							
Potassium	< 3.0 mEq/L	3.0	2.0	-	1.7	-	2.1
Hematology High							
Eosinophils	> 1.0 x 10 ⁹ /L	2.6	3.3	-	2.6	1.7	0.7
Neutrophils	> 20 x 10 ⁹ /L	2.3	1.3	-	-	-	-
Hematology Low							
Hematocrit	< 30%	17.3	22.0	2.6	-	0.8	0.7
Hemoglobin	< 80 g/L	3.8	3.9	0.9	-	-	-
Neutrophils	≤ 0.5 x 10 ⁹ /L	6.0	8.3	-	-	-	-
Red Blood Cells (RBC)	< 3.0 x 10 ¹² /L	18.6	24.4	1.8	-	5.9	-
White Blood Cells (WBC)	< 2.5 x 10 ⁹ /L	36.9	59.4	-	0.9	6.8	3.5

- Indicates no events reported.

Definitions: CK = creatinine; ULN = upper limit of the normal range; N/A = Not Applicable; SGPT/ALT = serum glutamic-pyruvic transaminase/alanine aminotransferase; SGOT/AST = serum glutamic-oxaloacetic transaminase/aspartate aminotransferase; GGT = gamma-glutamyl transpeptidase; ZDV = zidovudine.

8.5 Post-Market Adverse Reactions

The following adverse events have been reported during post-marketing use of ritonavir. Because these reactions are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or establish a causal relationship to ritonavir exposure.

Cardiovascular System:	First-degree AV block, second-degree AV block, third-degree AV block and right bundle branch block have been reported (see 7 WARNINGS AND PRECAUTIONS). Myocardial infarction has been reported. Cardiac and neurologic events have been reported when ritonavir has been co-administered with disopyramide, mexiletine, nefazodone, fluoxetine, and beta blockers. The possibility of drug interaction cannot be excluded.
Endocrine System:	Hyperglycemia has been reported in individuals with and without a known history of diabetes. Cushing's syndrome and adrenal suppression have been reported when ritonavir was co-administered with fluticasone propionate, budesonide or triamcinolone.
Hemic and Lymphatic System:	There have been reports of increased bleeding in patients with hemophilia A or B (see 7 WARNINGS AND PRECAUTIONS).
Immune System:	Immune Reconstitution Inflammatory Syndrome (see 7 WARNINGS AND PRECAUTIONS).
Metabolism and Nutrition Disorders:	Dehydration, usually associated with gastrointestinal symptoms, and sometimes resulting in hypotension, syncope, or renal insufficiency has been reported. Syncope, orthostatic hypotension, and renal insufficiency have also been reported without known dehydration. Co-administration of ritonavir with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system.
Nervous System Disorders:	There have been post-marketing reports of seizure. Cause and effect relationship have not been established.
Reproductive System and Breast Disorders:	Menorrhagia has been reported.
Skin and Subcutaneous Tissue Disorders:	Stevens-Johnson syndrome (SJS), and Toxic epidermal necrolysis (TEN).

9 DRUG INTERACTIONS

9.1 Serious Drug Interactions

Serious Drug Interactions

- **Co-administration** (saquinavir/ritonavir): The recommended dose of Auro-Ritonavir is 100 mg twice daily when used with saquinavir. Higher doses of ritonavir when given with saquinavir have been associated with severe adverse events mainly diabetic ketoacidosis and liver disorders, especially in patients with pre-existing liver disease
- **Co-administration** (saquinavir/rifampin/ritonavir): Saquinavir/Ritonavir should not be given together with rifampin, due to the risk of severe hepatotoxicity (presenting as increased hepatic transaminases) if the 3 drugs are given together.
- **Co-administration** (tipranavir/ritonavir): Tipranavir co-administered with 200 mg of ritonavir has been associated with reports of clinical hepatitis and hepatic decompensation including some fatalities. Extra vigilance is warranted in patients with chronic hepatitis B or hepatitis C co-infection, as these patients have an increased risk of hepatotoxicity.

9.2 Drug Interactions Overview

When Auro-Ritonavir is used as a pharmacokinetic enhancer with other protease inhibitors, see the full prescribing information of that protease inhibitor including information on drug interactions.

These examples are a guide and not considered a comprehensive list of all possible drugs that may interact with ritonavir. The healthcare provider should consult appropriate references for comprehensive information.

Potential for Ritonavir to Affect Other Drugs

Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co-administered with ritonavir. Thus, co-administration of ritonavir with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated. Co-administration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in **Table 6**.

Ritonavir also inhibits CYP2D6 to a lesser extent. Co-administration of substrates of CYP2D6 with ritonavir could result in increases (up to 2-fold) in the AUC of the other agent, possibly requiring

a proportional dosage reduction. Ritonavir also appears to induce CYP3A, CYP1A2, CYP2C9, CYP2C19, and CYP2B6 as well as other enzymes, including glucuronosyl transferase. Therefore, decreased plasma concentrations of the co-administered drugs and potential loss of therapeutic effects may signify the need for dosage alteration of these agents.

When co-administering Auro-Ritonavir with any agent having a narrow therapeutic margin, such as anticoagulants, anticonvulsants, and antiarrhythmics, special attention is warranted.

Potential for Other Drugs to Affect Ritonavir

Agents which increase CYP3A activity (e.g., phenobarbital, carbamazepine, dexamethasone, phenytoin, rifampin, and rifabutin) would be expected to increase the clearance of ritonavir resulting in decreased ritonavir plasma concentrations. Tobacco use is associated with an 18% decrease in the area under the concentration-time curve (AUC) of ritonavir.

9.3 Drug-Behavioural Interactions

Not applicable.

9.4 Drug-Drug Interactions

Table 6 lists the established and other potentially significant drug interactions. Alteration in dose or regimen may be recommended based on drug interaction studies or predicted interaction (see also **2 CONTRAINDICATIONS** and **Table 7** and **Table 8** for magnitude of interaction).

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Table 6 - Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen Recommended Based on Drug Interaction Studies or Predicted Interaction.

Concomitant Drug Class: Drug Name	Effect on Concentration of ritonavir or Concomitant Drug	Clinical Comment
HCV-Antiviral Agents		
HCV Combination Drug:		
ombitasvir/paritaprevir/ ritonavir with or without dasabuvir ^a	↑ paritaprevir	Exposures of paritaprevir may be increased when co-administered with ritonavir, therefore, co-administration is not recommended.
HCV Protease Inhibitors:		

Concomitant Drug Class: Drug Name	Effect on Concentration of ritonavir or Concomitant Drug	Clinical Comment
simeprevir ^a	↑ simeprevir	A pharmacokinetic study demonstrated that concomitant administration of simeprevir 200 mg once daily with ritonavir 100 mg twice daily resulted in an increase in simeprevir concentrations. It is not recommended to co-administer ritonavir with simeprevir.
glecaprevir/pibrentasvir	↑ glecaprevir	Coadministration with ritonavir is not recommended due to an increased risk of ALT elevations associated with increased glecaprevir exposure.
HIV-Antiretroviral Agents		
HIV Protease Inhibitors:		
fosamprenavir	↑ amprenavir (↑ AUC, ↑ C _{max} , ↑ C _{min})	Refer to the fosamprenavir Product Monograph for details on co-administration of fosamprenavir 700 mg twice daily with ritonavir 100 mg twice daily or fosamprenavir 1400 mg once daily with ritonavir 200 mg once daily.
atazanavir	↑ atazanavir (↑ AUC, ↑ C _{max} , ↑ C _{min})	Atazanavir plasma concentrations achieved with atazanavir 300 mg once daily and ritonavir 100 mg once daily are higher than those achieved with atazanavir 400 mg once daily. Refer to the atazanavir Product Monograph for details on co-administration of atazanavir 300 mg once daily, with ritonavir 100 mg once daily.
darunavir	↑ darunavir (↑ AUC, ↑ C _{max} , ↑ C _{min})	Refer to the darunavir Product Monograph for details on co-administration of darunavir 600 mg twice daily with ritonavir 100 mg twice daily.
indinavir ^a	↑ indinavir (↑ AUC, ↑ C _{max} , ↑ C _{min})	Alterations in concentrations are noted when reduced doses of indinavir are co-administered with reduced dose of ritonavir. The safety and efficacy of this combination have not yet been established. The risk of nephrolithiasis may be increased when doses of indinavir equal to or greater than 800 mg twice daily are given with ritonavir. Adequate hydration and monitoring of the patients is warranted.
nelfinavir	↑ M8 (major active metabolite of nelfinavir)	Ritonavir increases the concentrations of nelfinavir major active metabolite, M8. This interaction is likely to involve cytochrome P450 inhibition and induction.

Concomitant Drug Class: Drug Name	Effect on Concentration of ritonavir or Concomitant Drug	Clinical Comment
saquinavir	↑ saquinavir (↑ AUC, ↑ C _{max} , ↑ C _{min})	The recommended dosage regimen is saquinavir 1000 mg with ritonavir 100 mg twice daily taken within 2 hours after a meal. Dose adjustment may be needed if other HIV-protease inhibitors are used in combination with saquinavir and ritonavir. Saquinavir and ritonavir should not be given together with rifampin due to risk of severe hepatotoxicity (presenting as increased hepatic transaminases) if the 3 drugs are given together. In some cases, co-administration of saquinavir and ritonavir has led to severe adverse events, mainly diabetic ketoacidosis, and liver disorders, especially in patients with pre-existing liver disease. Refer to the saquinavir Product Monograph for prescribing information.
tipranavir	↑ tipranavir (↑ AUC, ↑ C _{max} , ↑ C _{min})	Refer to the tipranavir Product Monograph for details on co-administration of tipranavir 500 mg twice daily with ritonavir 200 mg twice daily.
Nucleoside Reverse Transcriptase Inhibitors:		
didanosine	↓ didanosine	Dosing of didanosine and ritonavir should be separated by 2.5 hours to avoid formulation incompatibility.
tenofovir	↑ tenofovir	Lopinavir/ritonavir has been shown to increase tenofovir concentrations. Higher tenofovir concentrations could potentiate tenofovir-associated adverse events, including renal disorders. Patients receiving ritonavir and tenofovir disoproxil fumarate should be monitored for tenofovir-associated adverse events. Refer to the tenofovir Product Monograph for more information.
Non-Nucleoside Reverse Transcriptase Inhibitors:		
delavirdine ^a	↑ ritonavir ↔ delavirdine	When used in combination with delavirdine, a dose reduction of ritonavir should be considered. Based on comparison to historical data, the pharmacokinetics of delavirdine did not appear to be affected by ritonavir. The safety and efficacy of this combination (delavirdine/ritonavir) have not been established.
efavirenz	↑ efavirenz	In healthy volunteers receiving 500 mg ritonavir twice daily with efavirenz 600 mg once daily, the steady state AUC was increased by 21%. An associated increase in the AUC of ritonavir of 17% was observed.
Integrase Inhibitor:		
raltegravir	↓ raltegravir	A pharmacokinetic study showed that co-administration of ritonavir 100 mg twice daily and raltegravir 400 mg single dose resulted in a reduction in raltegravir plasma concentration.

Concomitant Drug Class: Drug Name	Effect on Concentration of ritonavir or Concomitant Drug	Clinical Comment
CCR5 Antagonist:		
maraviroc	↑ maraviroc (↑ AUC, ↑ Cmax, ↑ Cmin)	When co-administered with reduced doses of ritonavir plasma levels of maraviroc increases. The dose of maraviroc should be decreased during co-administration with ritonavir. Refer to the maraviroc Product Monograph for details on co-administration of maraviroc 150 mg twice daily with ritonavir.
Other Agents		
Alpha1-adrenoreceptor Antagonist:		
alfuzosin	↑ alfuzosin	Based on results of a drug interaction study with ketoconazole, another potent inhibitor of CYP3A4, a significant increase in alfuzosin exposure is expected in the presence of ritonavir (600 mg twice daily). Therefore, alfuzosin is contraindicated with ritonavir (see 2 CONTRAINDICATIONS).
Analgesics, Narcotic:		
fentanyl tramadol propoxyphene ^a	↑ fentanyl ↑ tramadol ↑ propoxyphene	Ritonavir inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of fentanyl, tramadol, and propoxyphene. Careful monitoring of therapeutic and adverse effects (including respiratory depression) is recommended when ritonavir is co-administered with fentanyl, including extended-release, transdermal or transmucosal preparations. Use tramadol and propoxyphene with caution, dose reduction of these drugs may be needed.
methadone	↓ methadone	Dosage increase of methadone may be considered.
Anesthetic:		
meperidine	↓ meperidine ↑ normeperidine (metabolite)	Dosage increase and long-term use of meperidine with ritonavir are not recommended due to the increased concentrations of the metabolite normeperidine which has both analgesic activity and CNS stimulant activity (e.g., seizures).
Antiarrhythmics:		
disopyramide, lidocaine (systemic), mexiletine	↑ antiarrhythmics	Plasma concentrations of these drugs are expected to increase by co-administration with ritonavir. Use with caution, dose reduction of these drugs may be needed.
amiodarone, bepridil ^a , dronedarone, flecainide, propafenone, quinidine ^a	↑ antiarrhythmics	Co-administration may lead to serious and/or life-threatening reactions, such as cardiac arrhythmias. Therefore, use of these antiarrhythmics with ritonavir is contraindicated (see 2 CONTRAINDICATIONS).
Antibacterial:		

Concomitant Drug Class: Drug Name	Effect on Concentration of ritonavir or Concomitant Drug	Clinical Comment
fusidic acid	↑ fusidic acid ↑ ritonavir	Coadministration of protease inhibitors, including ritonavir with fusidic acid is expected to increase fusidic acid, as well as the protease inhibitor concentration in plasma (see 2 CONTRAINDICATIONS).
Anticancer agents:		
abemaciclib, apalutamide, dasatinib, encorafenib ibrutinib, neratinib, nilotinib, vincristine, vinblastine	↑ anticancer agents	<p>Serum concentrations increase when co- administered with ritonavir resulting in the potential for increased incidence of adverse events, some of which may be serious.</p> <p>Coadministration of ritonavir with ibrutinib is not recommended due to expected increase in ibrutinib exposure that could potentially result in a risk of tumor lysis syndrome.</p> <p>Coadministration of ritonavir with dasatinib should be avoided due to expected increase in dasatinib exposure. If the co-administration is unavoidable, close monitoring for toxicity and a dasatinib dose reduction should be considered (see SPRYCEL Product Monograph).</p> <p>Coadministration of encorafenib with ritonavir should be avoided due to potential increase in encorafenib exposure potentially increasing the risk of serious adverse events such as QT interval prolongation. If coadministration cannot be avoided, modify encorafenib dose as recommended in the encorafenib Product Monograph.</p> <p>Coadministration of ritonavir with nilotinib should be avoided due to expected increase in nilotinib exposure. If the co-administration is unavoidable, close monitoring for the QT interval prolongation is recommended (see TASIGNA Product Monograph).</p> <p>Concomitant use of ritonavir with apalutamide is contraindicated.</p> <p>Coadministration of ritonavir with abemaciclib should be avoided due to expected increase in abemaciclib exposure. If the co-administration is unavoidable, close monitoring for toxicity and abemaciclib dose reduction should be considered (see VERZENIO Product Monograph).</p> <p>Coadministration of ritonavir with neratinib is contraindicated due to expected increase in neratinib exposure (see 2 CONTRAINDICATIONS).</p>

Concomitant Drug Class: Drug Name	Effect on Concentration of ritonavir or Concomitant Drug	Clinical Comment
venetoclax	↑ venetoclax	Concomitant use of strong CYP3A inhibitors, such as ritonavir, and venetoclax may increase the risk of tumor lysis syndrome at the dose initiation and during the ramp-up phase (see 2 CONTRAINDICATIONS). For patients who have completed the ramp- up phase and are on a steady daily dose of venetoclax, reduce the venetoclax dose by at least 75% when used with strong CYP3A inhibitors (see VENCLEXTA Product Monograph).
Anticoagulants:		
rivaroxaban	↑ rivaroxaban	A study has shown that co-administration of ritonavir and rivaroxaban resulted in increased exposure of rivaroxaban which may lead to risk of increased bleeding. Ritonavir and rivaroxaban should not be used concomitantly (see 2 CONTRAINDICATIONS).
warfarin	↓ R-warfarin ↓ ↑ S-warfarin	Initial frequent monitoring of the INR (International Normalized Ratio) during ritonavir and warfarin co-administration is indicated.
Anticonvulsants:		
clonazepam ethosuximide divalproex lamotrigine	↑ clonazepam ↑ ethosuximide ↓ divalproex ↓ lamotrigine	Plasma concentrations of clonazepam and ethosuximide are expected to increase by co- administration with ritonavir. Use with caution, dose reduction of these drugs may be needed. Plasma concentrations of divalproex and lamotrigine are expected to decrease by co- administration with ritonavir. Use with caution, dose increase of these drugs may be needed.
carbamazepine, phenobarbital, phenytoin	↑ carbamazepine ↓ phenytoin ↓ ritonavir	Plasma concentrations of carbamazepine are expected to increase by co-administration with ritonavir. Use with caution, dose reduction of carbamazepine may be needed. Plasma concentrations of phenytoin are expected to decrease by co-administration with ritonavir. Use with caution, dose increase of phenytoin may be needed. Carbamazepine, phenobarbital, phenytoin, which increase CYP3A activity, would be expected to increase the clearance of ritonavir resulting in decreased ritonavir plasma concentrations. Use with caution, dose adjustment of ritonavir may be needed.
Antidepressants:		

Concomitant Drug Class: Drug Name	Effect on Concentration of ritonavir or Concomitant Drug	Clinical Comment
mitriptyline, clomipramine, fluoxetine, imipramine, maprotiline, nefazodone, nortriptyline, paroxetine, sertraline, trimipramine, venlafaxine	↑ antidepressants	Ritonavir dosed as an antiretroviral agent may inhibit CYP2D6 and result in increased plasma exposure of these drugs. Ritonavir dosed as a pharmacokinetic enhancer is not expected to result in any clinically meaningful increases in CYP2D6 substrates. Use with caution, dose reduction of these drugs may be needed.
bupropion	↓ bupropion	Bupropion is primarily metabolized by CYP2B6. Concurrent administration of bupropion with repeated doses of ritonavir decreases bupropion levels.
desipramine	↑ desipramine	A study has shown that co-administration of ritonavir and desipramine resulted in increased exposure of desipramine. Dosage reduction and concentration monitoring of desipramine is recommended.
trazodone	↑ trazodone	Concomitant use of ritonavir and trazodone increases concentrations of trazodone. Adverse events of nausea, dizziness, hypertension, and syncope have been observed. If trazodone is used with a CYP3A4 inhibitor, such as ritonavir, the combination should be used with caution and a lower dose of trazodone should be considered.
Antiemetics:		
dronabinol	↑ dronabinol	Plasma concentrations of dronabinol are expected to increase by co-administration with ritonavir. Use with caution, dose reduction of dronabinol may be needed.
Antifungal:		
ketoconazole	↑ ketoconazole	High doses of ketoconazole or itraconazole (> 200 mg/day) are not recommended.
itraconazole	↑ itraconazole	
Antigout:		

Concomitant Drug Class: Drug Name	Effect on Concentration of ritonavir or Concomitant Drug	Clinical Comment
colchicine	↑ colchicine	<p><u>For patients with renal and/or hepatic impairment:</u></p> <ul style="list-style-type: none"> Life-threatening and fatal drug interactions have been reported in patients treated with colchicine and ritonavir. For patients with renal and/or hepatic impairment co- administration of colchicine with ritonavir is contraindicated (see 2 CONTRAINDICATIONS). <p><u>For patients with normal renal and/or hepatic function:</u></p> <ul style="list-style-type: none"> <i>Treatment of gout flares:</i> 0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Dose to be repeated no earlier than 3 days. <i>Prophylaxis of gout flares:</i> If the original colchicine regimen was 0.6 mg twice daily, the regimen should be adjusted to 0.3 mg once a day. If the original colchicine regimen was 0.3 mg twice daily, the regimen should be adjusted to 0.3 mg once every other day. <i>Treatment of Familial Mediterranean fever (FMF):</i> Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).
Anti-infective:		
clarithromycin	↑ clarithromycin	<p>For patients with renal impairment, the following dosage adjustments should be considered:</p> <ul style="list-style-type: none"> For patients with CLCR 30 to 60 mL/min the dose of clarithromycin should be reduced by 50%. For patients with CLCR < 30 mL/min the dose of clarithromycin should be reduced by 75%. <p>No dose adjustment for patients with normal renal function is necessary.</p>
Antimycobacterial:		
rifabutin	↑ rifabutin and rifabutin metabolite ↓ ritonavir	Dosage reduction of rifabutin by at least three-quarters of the usual dose of 300 mg/day is recommended (e.g. 150 mg every other day or three times a week). Further dosage reduction may be necessary.
rifampin	↓ ritonavir	May lead to loss of virologic response. Alternate antimycobacterial agents, such as rifabutin should be considered (see Antimycobacterial: rifabutin) for dose reduction recommendations.
Antiparasitics:		

Concomitant Drug Class: Drug Name	Effect on Concentration of ritonavir or Concomitant Drug	Clinical Comment
atovaquone	↓ atovaquone	Plasma concentrations of atovaquone are expected to decrease by co-administration with ritonavir. Use with caution, dose increase of atovaquone may be needed.
quinine	↑ quinine	Plasma concentrations of quinine are expected to increase by co-administration with ritonavir. Use with caution, dose reduction of quinine may be needed.
Anxiolytics/Sedative/Hypnotics:		
midazolam, oral ^a	↑ midazolam	Midazolam is extensively metabolized by CYP3A4. Increases in the concentration of midazolam are expected to be significantly higher with oral than parenteral administration. Co-administration of oral midazolam with ritonavir is contraindicated (see 2 CONTRAINDICATIONS).
midazolam, parenteral	↑ midazolam	Concomitant use of parenteral midazolam with ritonavir may increase plasma concentrations of midazolam. Co-administration should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered.
buspirone, clorazepate, diazepam, estazolam ^a , flurazepam, zolpidem	↑ Anxiolytics/Sedatives/Hypnotics	Plasma concentrations of these drugs are expected to increase by co-administration with ritonavir. Use with caution, dose reduction of these drugs may be needed.
Beta-blockers:		
metoprolol, timolol	↑ beta-blockers	Plasma concentrations of these drugs are expected to increase by co-administration with ritonavir. Use with caution, dose reduction of these drugs may be needed.
Bronchodilator:		
theophylline	↓ theophylline	Increased dosage of theophylline may be required; therapeutic monitoring should be considered.
Calcium channel blockers:		
diltiazem, nifedipine, verapamil	↑ calcium channel blockers	Plasma concentrations of these drugs are expected to increase by co-administration with ritonavir. Use with caution, dose reduction of these drugs may be needed.
Corticosteroids:		

Concomitant Drug Class: Drug Name	Effect on Concentration of ritonavir or Concomitant Drug	Clinical Comment
fluticasone propionate, budesonide, triamcinolone	↑ fluticasone ↑ budesonide ↑ triamcinolone	Concomitant use of ritonavir and inhaled, injectable, or intranasal fluticasone propionate, budesonide, triamcinolone, or other glucocorticoids that are metabolized by CYP3A4 are not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid side effects, including Cushing's syndrome and adrenal suppression. Concomitant use of ritonavir and fluticasone propionate, budesonide or triamcinolone can significantly increase fluticasone propionate, budesonide, or triamcinolone plasma concentrations and reduce serum cortisol concentrations. Consider alternatives to fluticasone propionate, budesonide or triamcinolone particularly for long-term use.
dexamethasone prednisone	↑ dexamethasone ↓ ritonavir ↑ prednisone	Dexamethasone, which increases CYP3A activity, would be expected to increase the clearance of ritonavir resulting in decreased ritonavir plasma concentrations. Plasma concentrations of dexamethasone and prednisone are expected to increase by co-administration with ritonavir. Use with caution, dose adjustment of these drugs may be needed.
digoxin	↑ digoxin	A literature report has shown that co-administration of ritonavir (300 mg every 12 hours) and digoxin resulted in significantly increased digoxin levels. Caution should be exercised when co-administering ritonavir and digoxin, with appropriate monitoring of serum levels.
Endothelin receptor antagonist:		
bosentan	↑ bosentan	Co-administration of bosentan in patients already on ritonavir for at least 10 days: Start at 62.5 mg once daily or every other day based upon individual tolerability. Coadministration of ritonavir in patients on bosentan: Discontinue use of bosentan at least 36 hours prior to initiation of ritonavir. After at least 10 days following the initiation of ritonavir, resume bosentan at 62.5 mg once daily or every other day based upon individual tolerability.
Gonadotropin releasing hormone (GnRH) receptor antagonist		

Concomitant Drug Class: Drug Name	Effect on Concentration of ritonavir or Concomitant Drug	Clinical Comment
elagolix	↑ elagolix	Coadministration of elagolix with ritonavir could increase elagolix exposure due to inhibition of CYP3A and P-gp. Known serious adverse events for elagolix include suicidal ideation and hepatic transaminase elevations. In addition, elagolix is a weak/moderate inducer of CYP3A, which may decrease exposure of ritonavir. Refer to the elagolix label for dosing information with strong CYP-3A4 inhibitors.
Hypolipidemics, HMG- CoA Reductase Inhibitors:		
lovastatin, simvastatin	↑ lovastatin, simvastatin	The HMG-CoA reductase inhibitors simvastatin and lovastatin are highly dependent on CYP3A for metabolism, thus concomitant use of ritonavir with simvastatin or lovastatin is contraindicated due to an increased risk of myopathy including rhabdomyolysis (see 2 CONTRAINDICATIONS).
lomitapide	↑ lomitapide	Lomitapide is a sensitive substrate for CYP3A4 metabolism. CYP3A4 inhibitors increase the exposure of lomitapide, with strong inhibitors increasing exposure approximately 27-fold. Concomitant use of moderate or strong CYP3A4 inhibitors with lomitapide is contraindicated.
atorvastatin, rosuvastatin	↑ atorvastatin, rosuvastatin	Caution must also be exercised and reduced doses should be considered if ritonavir is used concurrently with atorvastatin, which is metabolized to a lesser extent by CYP3A4. While rosuvastatin elimination is not dependent on CYP3A, an elevation of rosuvastatin exposure has been reported with ritonavir co-administration. Use the lowest doses of atorvastatin or rosuvastatin with careful monitoring for signs and symptoms of myopathy or rhabdomyolysis. If treatment with an HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Immunosuppressants :		
cyclosporine, everolimus, tacrolimus, rapamycin ^a	↑ immunosuppressants	Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with ritonavir.
Kinase inhibitors (also see Anticancer agents above):		
fostamatinib	↑ fostamatinib	Coadministration of fostamatinib with ritonavir could increase fostamatinib metabolite R406 exposure resulting in dose-related adverse events such as hepatotoxicity and neutropenia. Monitor for toxicities of fostamatinib that may require fostamatinib dose modification (see fostamatinib Product Monograph).
Neuroleptics/Antipsychotics:		

Concomitant Drug Class: Drug Name	Effect on Concentration of ritonavir or Concomitant Drug	Clinical Comment
lurasidone	↑ lurasidone	Due to CYP3A inhibition by ritonavir, concentrations of lurasidone are expected to increase. Co-administration of lurasidone with ritonavir is contraindicated (see 2 CONTRAINDICATIONS).
perphenazine, risperidone, thioridazine ^a	↑ neuroleptics	Ritonavir dosed as an antiretroviral agent may inhibit CYP2D6 resulting in increases in the plasma concentration of perphenazine, risperidone, and thioridazine. Ritonavir dosed as a pharmacokinetic enhancer is not expected to result in any clinically meaningful increases in CYP2D6 substrates. Use with caution, dose reduction of these drugs may be needed.
pimozide	↑ pimozide	Co-administration of ritonavir with pimozide is contraindicated as it may lead to serious and/or life-threatening reactions, such as cardiac arrhythmias (see 2 CONTRAINDICATIONS).
quetiapine	↑ quetiapine	Due to inhibition of CYP3A by ritonavir (ritonavir), co-administration of ritonavir with quetiapine may result in increased quetiapine concentrations. Serious and life-threatening quetiapine-related adverse reactions have been reported with CYP3A inhibitors. Ritonavir should not be used in combination with quetiapine. Monitoring and dose reduction may be required if necessary.
Oral Contraceptive or Patch Contraceptive:		
ethinyl estradiol	↓ ethinyl estradiol	Dosage increase or alternate contraceptive measures should be considered.
PDE5 Inhibitors:		

Concomitant Drug Class: Drug Name	Effect on Concentration of ritonavir or Concomitant Drug	Clinical Comment
sildenafil, tadalafil, vardenafil	↑ sildenafil	Particular caution should be used when prescribing PDE5 inhibitors for the treatment of erectile dysfunction in patients receiving ritonavir. Co-administration of Ritonavir with these drugs is expected to substantially increase their concentrations and may result in increase in associated adverse events, such as hypotension, syncope, visual changes, and prolonged erection. <u>Use of PDE5 Inhibitors for Erectile Dysfunction</u> Sildenafil may be used with caution at reduced doses of 25 mg every 48 hours with increased monitoring for adverse events. Tadalafil may be used with caution at reduced doses of 10 mg every 72 hours with increased monitoring for adverse events. Vardenafil should not be used with ritonavir (see 2 CONTRAINDICATIONS). <u>Use of PDE5 Inhibitors for Pulmonary Arterial Hypertension</u> Coadministration of ritonavir and tadalafil for the treatment of pulmonary arterial hypertension is not recommended. The use of sildenafil or vardenafil is contraindicated with ritonavir (see 2 CONTRAINDICATIONS).
Stimulants:		
methamphetamine	↑ methamphetamine	Ritonavir dosed as an antiretroviral agent may inhibit CYP2D6 and as a result is expected to increase concentrations of amphetamine and its derivatives. Ritonavir dosed as a pharmacokinetic enhancer is not expected to result in any clinically meaningful increases in CYP2D6 substrates. Use with caution, dose reduction of these drugs may be needed.

a. Products not marketed in Canada.

↑ Indicates increase; ↓ indicates decrease; ↔ indicates no change.

Assessment of Drug Interactions

For details regarding the ritonavir pharmacokinetics refer to section (**10.3 Pharmacokinetics**).

The effects of co-administration of ritonavir on the AUC, C_{max}, and C_{min} are summarized in **Table 7** and **Table 8**.

Table 7. Drug Interactions: Pharmacokinetic Parameters for Ritonavir in the Presence of the Co-administered Drug (See Table 6 for Recommended Alterations in Dose or Regimen)

Co-Administered Drug	Dose of Co-Administered Drug	Ritonavir Dosage	n	AUC % (95% CI)	C _{max} % (95% CI)	C _{min} % (95% CI)
Antidepressants						
Fluoxetine	30 mg every 12 h 8 days	600 mg single dose	16	↑ 19% (7, 34%)	↔	ND
Antifungal						
Fluconazole	400 mg Day 1, 200 mg daily 4 days	200 mg every 6 h 4 days	8	↑ 12% (5, 20%)	↑ 15% (7, 22%)	↑ 14% (0, 26%)
Ketoconazole	200 mg daily 7 days	500 mg every 12 h 10 days	12	↑ 18% (-3, 52%)	↑ 10% (-11, 36%)	ND
Voriconazole	400 mg every 12 h, 1 day; then 200 mg every 12h 8 days	400 mg every 12 h 9 days	17	↔	↔	ND
Anti-infective						
Clarithromycin	500 mg every 12 h 4 days	200 mg every 8 h 4 days	22	↑ 12% (2, 23%)	↑ 15% (2, 28%)	↑ 14% (-3, 36%)
Antimycobacterial						
Rifampin	600 mg or 300 mg daily 10 days	500 mg every 12 h 20 days	7, ^{9a}	↓ 35% (7, 55%)	↓ 25% (-5, 46%)	↓ 49% (-14, 91%)
HIV-Antiretroviral Agents						
Didanosine	200 mg every 12 h 4 days, about 2.5 h before ritonavir	600 mg every 12 h 4 days	12	↔	↔	↔
Zidovudine	200 mg every 8 h 4 days	300 mg every 6 h 4 days	10	↔	↔	↔
<p>↑ Indicates increase; ↓ indicates decrease; ↔ indicates no change.</p> <p>a. Parallel group design; entries are subjects receiving combination and control regimens, respectively. Definitions: h = hour; ND = not detected</p>						

Table 8. Drug Interactions: Pharmacokinetic Parameters for Co-administered Drug in the Presence of ritonavir (See Table 6 for Recommended Alterations in Dose or Regimen)

Co-Administered Drug	Dose of Co-Administered Drug	Ritonavir Dosage	n	AUC % (95% CI)	C _{max} % (95% CI)	C _{min} % (95% CI)
Analgesics, Narcotic						
Methadone ^a	5 mg single dose	500 mg every 12 h 15 days	11	↓ 36% (16, 52%)	↓ 38% (28, 46%)	ND
Anesthetic						
Meperidine	50 mg oral single dose	500 mg every 12 h 10 days	8	↓ 62% (59, 65%)	↓ 59% (42, 72%)	ND
Normeperidine metabolite			6	↑ 47% (-24, 345%)	↑ 87% (42, 147%)	ND
Anticoagulants						
Warfarin S-Warfarin R-Warfarin	5 mg single dose	400 mg every 12 h 12 days	12	↑ 9% (-17, 44%) ^b ↓ 33% (-38, -27%) ^b	↓ 9% (-16, -2%) ^b ↔	ND ND
Antidepressant						
Trazodone	50 mg single dose	200 mg every 12 h 10 days	10	↑ 2.4-fold	↑ 34%	
Desipramine 2-OH desipramine metabolite	100 mg single dose	500 mg every 12 h 12 days	14	↑ 145% (103, 211%) ↓ 15% (3, 26%)	↑ 22% (12, 35%) ↓ 67% (62, 72%)	ND ND
Antifungal						
Ketoconazole	200 mg daily 7 days	500 mg every 12 h 10 days	12	↑ 3.4-fold (2.8, 4.3X)	↑ 55% (40, 72%)	ND
Voriconazole	400 mg every 12 h, 1 day; then 200 mg every 12 h 8 days	400 mg every 12 h 9 days	17	↓ 82%	↓ 66%	Not reported
Anti-infective						

Co-Administered Drug	Dose of Co-Administered Drug	Ritonavir Dosage	n	AUC % (95% CI)	C _{max} % (95% CI)	C _{min} % (95% CI)
Clarithromycin	500 mg every 12 h 4 days	200 mg every 8 h 4 days	22	↑ 77% (56, 103%)	↑ 31% (15, 51%)	↑ 2.8-fold (2.4, 3.3X)
14-OH clarithromycin metabolite				↓ 100%	↓ 99%	↓ 100%
Antimicrobial						
Sulfamethoxazole ^c	800 mg single dose	500 mg every 12 h 12 days	15	↓ 20% (16, 23%)	↔	ND
Trimethoprim ^c	160 mg single dose	500 mg every 12 h 12 days	15	↑ 20% (3, 43%)	↔	ND
Antimycobacterial						
Rifabutin	150 mg daily 16 days	500 mg every 12 h 10 days	5,11 ^h	↑ 4-fold (2.8, 6.1X)	↑ 2.5-fold (1.9, 3.4X)	↑ 6-fold (3.5, 18.3X)
25-O-desacetyl rifabutin metabolite				↑ 38-fold (28, 56X)	↑ 16-fold (13, 20X)	↑ 181-fold (ND)
Bronchodilator						
Theophylline	3 mg/kg every 8 h 15 days	500 mg every 12 h 10 days	13, 11 ^h	↓ 43% (42, 45%)	↓ 32% (29, 34%)	↓ 57% (55, 59%)
CCR5 Antagonist						
Maraviroc	100 mg every 12 h	100 mg every 12 h	8	↑ 28%	↑ 161%	Not reported
Corticosteroid						
Fluticasone propionate aqueous nasal spray	200 mcg daily 7 days	100 mg every 12 h 7 days	18	↑ approx. 350-fold ^e	↑ approx. 25-fold ^e	
HIV-Antiretroviral Agents						
Atazanavir	300 mg every 24 h Days 1 to 20	100 mg every 24 h Days 11 to 20	28	↑ 3.4-fold	↑ 1.9-fold	↑ 11.9-fold

Co-Administered Drug	Dose of Co-Administered Drug	Ritonavir Dosage	n	AUC % (95% CI)	C _{max} % (95% CI)	C _{min} % (95% CI)
Darunavir	800 mg single dose	Titrated: 300 to 600 mg every 12 h over 6 days	8	↑ 9.2-fold	↑ 2-fold	Not reported
Didanosine	200 mg every 12 h 4 days, about 2.5 h before ritonavir	600 mg every 12 h 4 days	12	↓ 13% (0, 23%)	↓ 16% (5, 26%)	↔
Indinavir ^d	400 mg every 12 h	400 mg every 12 h	10	↑ 6% (-14, 29%)	↓ 51% (40, 61%)	↑ 4-fold (2.8, 6.8X)
Day 14	15 days	15 days		↓ 7% (-22, 28%)	↓ 62% (52, 70%)	↑ 4-fold (2.5, 6.5X)
Saquinavir ^f	400 mg every 12 h steady-state	400 mg every 12 h steady-state	7	↑ 17-fold (9, 31X)	↑ 14-fold (7, 28X)	ND
Raltegravir	400 mg single dose	100 mg every 12 h 16 days	10	↓ 16% (-30, 1%)	↓ 24% (-45, 4%)	↓ 1% (-30, 40%)
Zidovudine	200 mg every 8 h 4 days	300 mg every 6 h 4 days	9	↓ 25% (15, 34%)	↓ 27% (4, 45%)	ND
Oral Contraceptive or Patch Contraceptive						
Ethinyl estradiol	50 mcg single dose	500 mg every 12 h 16 days	23	↓ 40% (31, 49%)	↓ 32% (24, 39%)	ND
PDE5 Inhibitors						
Sildenafil	100 mg single dose	500 mg b.i.d. ^g 8 days	28	↑ 11-fold	↑ 4-fold	ND
Tadalafil	20 mg single dose	200 mg every 12 h		↑ 124%	↔	ND
Vardenafil	5 mg	600 mg every 12 h		↑ 49-fold	↑ 13-fold	ND
Sedative/hypnotics						

Co-Administered Drug	Dose of Co-Administered Drug	Ritonavir Dosage	n	AUC % (95% CI)	C _{max} % (95% CI)	C _{min} % (95% CI)
Alprazolam	1 mg single dose	500 mg every 12 h 10 days	12	↓ 12% (-5, 30%)	↓ 16% (5, 27%)	ND

a. Effects were assessed on a dose normalized comparison to a methadone 20 mg single dose.

b. 90% CI presented for R- and S-warfarin AUC and Cmax ratios.

c. Sulfamethoxazole and trimethoprim taken as single combination tablet.

d. Ritonavir and indinavir were co-administered for 15 days; Day 14 doses were administered after a 15% fat breakfast (757 Kcal) and 9% fat evening snack(236 Kcal), and Day 15 doses were administered after a 15% fat breakfast (757 Kcal)and 32% fat dinner (815 Kcal). Indinavir Cmin was also increased 4-fold. Effects were assessed relative to an indinavir 800 mg every 8h regimen under fasting conditions.

e. This significant increase in plasma fluticasone propionate exposure resulted in a significant decrease (86%) in plasma cortisol AUC.

f. Comparison to a standard saquinavir 600 mg every 8h regimen (n = 114).

g. Subjects in the entire study, a subset of subjects were administered the specified regimen.

h. Parallel group design; entries are subjects receiving combination and control regimens, respectively.

↑ Indicates increase; ↓ indicates decrease; ↔ indicates no change.
Definitions: b.i.d. =twice daily; ND=not detected.

9.5 Drug-Food Interactions

It is recommended that ritonavir be taken with meals, if possible. Refer to **10.3 Pharmacokinetics** and to **14 CLINICAL TRIALS** for information on the effect of food on ritonavir pharmacokinetics.

9.6 Drug-Herb Interactions

Concomitant use of ritonavir and St. John's wort (*Hypericum perforatum*) or products containing St. John's wort is contraindicated. Co-administration of protease inhibitors, including ritonavir, with St. John's wort is expected to substantially decrease protease inhibitor concentrations and may result in sub-optimal levels of ritonavir and lead to loss of virologic response and possible resistance to ritonavir or to the class of protease inhibitors (see **2 CONTRAINDICATIONS**).

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 ACTION AND CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Ritonavir is an inhibitor of HIV protease with activity against the Human Immunodeficiency Virus (HIV).

Ritonavir is an orally active peptidomimetic inhibitor of both the HIV-1 and HIV-2 proteases. Inhibition of HIV protease renders the enzyme incapable of processing the *gag-pol* polyprotein precursor which leads to the production of HIV particles with immature morphology that are unable to initiate new rounds of infection. Ritonavir has selective affinity for the HIV protease and has little inhibitory activity against human aspartyl proteases.

10.2 Pharmacodynamics

In vitro data indicate that ritonavir is active against all strains of HIV tested in a variety of transformed and primary human cell lines. The concentration of drug that inhibits 50% and 90% (EC₅₀, EC₉₀) of viral replication is approximately 0.02 and 0.11 microM, respectively. Studies which measured direct cell toxicity of ritonavir on several cell lines showed no direct toxicity at concentrations up to 25 microM, with a resulting in vitro therapeutic index of at least 1000.

Effects on the Electrocardiogram

A Phase 1, multiple-dose, open-label, placebo and active controlled (moxifloxacin 400 mg once daily), randomized crossover study was conducted in healthy volunteers. Ritonavir was dosed at 400 mg twice daily and on Day 3, ritonavir concentrations were approximately 1.5 fold higher than that observed with the 600 mg twice daily dose at steady state. At these increased concentrations, the maximum increase in QTcF was 5.5 msec. This increase is not clinically significant. No subject experienced an increase in QTcF of ≥ 60 msec from baseline or a QTcF interval exceeding the potentially clinically relevant threshold of 500 msec. Maximum PR interval was 252 msec and no second or third degree heart block was observed. Exposure-response analysis predicted that the PR effect of ritonavir plateaus around 20 msec, thus ritonavir 600 mg twice daily is unlikely to result in clinically significant PR prolongation (see **7 WARNINGS AND PRECAUTIONS**).

10.3 Pharmacokinetics

The pharmacokinetics of ritonavir have been studied in healthy volunteers and HIV-infected patients (CD4 ≥ 50 cells/microliter). See **Table 9** for ritonavir pharmacokinetic characteristics.

Table 9 - Ritonavir Pharmacokinetic Characteristics

Parameter	n	Values (Mean \pm SD)
C _{max} SS ^a	10	11.2 \pm 3.6 mcg/mL
C _{trough} SS ^a	10	3.7 \pm 2.6 mcg/mL

V_B/F^b	91	0.41 ± 0.25 L/kg
$t_{1/2}$		3 to 5 h
CL/F SS ^a	10	8.8 ± 3.2
CL/F ^b	91	4.6 ± 1.6
CLR	62	< 0.1 L/h
RBC/Plasma Ratio		0.14
Percent Bound ^c		98 to 99%

a. SS = steady state; patients taking ritonavir 600 mg every 12h.

b. Single ritonavir 600 mg dose.

c. Primarily bound to human serum albumin and alpha-1 acid glycoprotein over the ritonavir concentration range of 0.01 to 30 mcg/mL.

Absorption

Ritonavir tablets are not bioequivalent to ritonavir capsules. Under moderate fat conditions (857 kcal; 31% fat, 13% protein, 56% carbohydrates), when a single 100 mg ritonavir dose was administered as a tablet compared with a capsule, $AUC(0-\infty)$ met equivalence criteria but mean C_{max} was increased by 26% (92.8% confidence intervals: +15 to +39%).

Effect of Food on Oral Absorption

A food effect is observed for ritonavir tablets. Food decreased the bioavailability of the ritonavir tablets when a single 100 mg dose of ritonavir was administered. Under high fat conditions (907 kcal; 52% fat, 15% protein, 33% carbohydrates), a 23% decrease in mean $AUC(0-\infty)$ [90% confidence intervals: -30 to -15%], and a 23% decrease in mean C_{max} [90% confidence intervals: -34 to -11%] was observed relative to fasting conditions. Under moderate fat conditions, a 21% decrease in mean $AUC(0-\infty)$ [90% confidence intervals: -28 to -13%], and a 22% decrease in mean C_{max} [90% confidence intervals: -33 to -9%] was observed relative to fasting conditions.

However, the type of meal administered did not change ritonavir tablet bioavailability when high fat was compared to moderate fat meals.

Distribution

The protein binding of ritonavir in human plasma was noted to be approximately 98 to 99%. Ritonavir binds to both human α -1-acid glycoprotein (AAG) and human serum albumin (HSA) with comparable affinities. Total plasma protein binding is constant over the concentration range of 1 to 100 mcg/mL.

Tissue distribution studies with ¹⁴C-labeled ritonavir in rats showed the liver, adrenals, pancreas, kidneys and thyroid to have the highest concentrations of drug. Tissue to plasma ratios of approximately one, measured in rat lymph nodes, suggest that ritonavir distributes into lymphatic tissue. Ritonavir penetrates minimally into the brain.

Metabolism

Nearly all of the plasma radioactivity after a single oral 600 mg dose of ¹⁴C-ritonavir oral solution (n = 5) was attributed to unchanged ritonavir. Five ritonavir metabolites have been identified in human urine and feces. The isopropyl thiazole oxidation metabolite (M-2) is the major metabolite and has antiviral activity similar to that of parent drug; however, the concentrations of this metabolite in plasma are low. Studies utilizing human liver microsomes have demonstrated that cytochrome P450 3A (CYP3A) is the major isoform involved in ritonavir metabolism, although CYP2D6 also contributes to the formation of M-2.

Elimination

In a study of 5 subjects receiving a 600 mg dose of ¹⁴C-ritonavir oral solution, 11.3 ± 2.8% of the dose was excreted into the urine, with 3.5 ± 1.8% of the dose excreted as unchanged parent drug. In that study, 86.4 ± 2.9% of the dose was excreted in the feces with 33.8 ± 10.8% of the dose excreted as unchanged parent drug. Upon multiple dosing, ritonavir accumulation is less than predicted from a single dose possibly due to a time and dose-related increase in clearance.

Special Populations and Conditions

- **Pediatrics**

The pharmacokinetic profile of ritonavir in pediatric patients below the age of 2 years has not been established. Steady-state pharmacokinetics were evaluated in 37 HIV-infected patients ages 2 to 14 years receiving doses ranging from 250 mg/m² twice daily to 400 mg/m² twice daily. Across dose groups, ritonavir steady-state oral clearance (CL/F/m²) was approximately 1.5 times faster in pediatric patients than in adult subjects. Ritonavir concentrations obtained after 350 to 400 mg/m² twice daily in pediatric patients were comparable to those obtained in adults receiving 600 mg (approximately 330 mg/m²) twice daily.

- **Geriatrics**

No age-related pharmacokinetic differences have been observed in adult patients (18 to 63 years). Ritonavir pharmacokinetics have not been studied in older patients.

- **Sex**

A study of ritonavir pharmacokinetics in healthy males and females showed no statistically significant differences in the pharmacokinetics of ritonavir.

- **Ethnic origin**

Pharmacokinetic differences due to race have not been identified.

- **Hepatic Insufficiency**

In 6 HIV-infected adult subjects with mild hepatic insufficiency dosed with ritonavir 400 mg twice daily, ritonavir exposures were similar to control subjects dosed with 500 mg twice daily. Results indicate that dose adjustment is not required in patients with mild hepatic impairment.

Adequate pharmacokinetic data are not available for patients with moderate hepatic impairment. Protein binding of ritonavir was not statistically significantly affected by mildly or moderately impaired hepatic function.

- **Renal Insufficiency**

Ritonavir pharmacokinetics have not been studied in patients with renal insufficiency; however, since renal clearance is negligible, a decrease in total body clearance is not expected in patients with renal insufficiency.

Because ritonavir is highly protein bound it is unlikely that it will be significantly removed by dialysis (see **5 OVERDOSAGE**).

- **Obesity**

Ritonavir pharmacokinetic parameters were not statistically significantly associated with body weight or lean body mass.

11 STORAGE, STABILITY AND DISPOSAL

Temperature:

Store between 15°C to 30°C. Dispense in original container, exposure of the product to high humidity outside the original tight container is not recommended.

Others:

Keep out of reach and sight of children.

12 SPECIAL HANDLING INSTRUCTIONS

Not Applicable.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Ritonavir


Nonproprietary name: Ritonavir

Chemical name: Thiazol-5-ylmethyl [1S,2S,4S)-1-benzyl-2-hydroxy-4-[[[(2S)-3-methyl-2-[[methyl[[2-(1-methylethyl)thiazol-4-yl]methyl]carbamoyl]amino]butanoyl]amino]-5-phenylpentyl]carbamate

Molecular formula: $C_{37}H_{48}N_6O_5S_2$

Molecular mass: 721 g/mol

Structural formula:



Physicochemical properties: White or almost white powder.

Solubility: Freely soluble in methanol and in methylene chloride, very slightly soluble in acetonitrile, practically insoluble in water

14 CLINICAL TRIALS

14.1 Trial Design and Study Demographics

The activity of ritonavir as monotherapy or in combination with nucleoside reverse transcriptase inhibitors has been evaluated in 1446 patients enrolled in 2 double-blind, randomized trials. Ritonavir therapy in combination with zidovudine and zalcitabine was also evaluated in an open-label, non-comparative study of 32 patients.

Table 10 - Summary of Patient Demographics for Clinical Trials in Specific Indication

Study #	Trial Design	Dosage, Route of Administration and Duration	Study Subjects	Mean Age (Range)	Gender Race (% M/F) (%C/O) ^a	Mean Baseline CD4 Cell Count (Range)
Advanced Patients with Prior Antiretroviral Therapy						
M94-247	Double blind, randomized, 2-arm, parallel, multicenter international	Ritonavir liquid or semi-solid capsules (600 mg b.i.d.) vs. Placebo Oral 6 months double-blind followed by 14 months open-label follow-up	1090	38.9 years (15-72)	92/8 86/14	32 cells/microliter (0-154) ^b
Patients Without Prior Antiretroviral Therapy						
M94-245	Double blind, randomized, 3-arm, parallel, multicenter	Ritonavir liquid or semi-solid capsules (600 mg b.i.d.) vs. zidovudine Capsules (200 mg t.i.d.) vs. Ritonavir liquid or semi-solid capsules (600 mg b.i.d.) + zidovudine capsules (200 mg t.i.d.) Oral 8 to 12 months	356	36.0 years (18-69)	91/9 83/17	364 cells/microliter Range: 139-1054 (200-500) ^c
Combination Therapy in Anti-retroviral Naïve Patients						
M94-208	Phase II, open-label, multicenter	Triple Therapy Combination: Ritonavir (600 mg b.i.d.) + zidovudine (200 mg t.i.d.) + zalcitabine (0.75 mg t.i.d.) Oral 6 months	32	38.1 years (29-52)	88/12 97/3	Median: 83 > 100 cells/microliter (81%) ^d

a. % Male/Female; % Caucasian/Other

b. Approximately 50% of patients had baseline CD4 cell counts ≤ 20 cells/microliter, and only 22% had counts > 50 cells/microliter.

c. Approximately 75% of the patients were evenly distributed between this range

d. The majority (81%) of patients had baseline CD4 values > 100 cells/microliter

Definitions: b.i.d. = twice daily; t.i.d. = three times daily.

14.2 Study Results

Advanced Patients with Prior Antiretroviral Therapy

Study M94-247 was a randomized, double-blind trial conducted in HIV-infected patients with at least 9 months of prior antiretroviral therapy and baseline CD4 cells counts ≤ 100 cells/microliter. Ritonavir 600 mg twice daily or placebo was added to each patient's baseline antiretroviral therapy regimen, which could have consisted of up to 2 approved antiretroviral agents. The study accrued 1090 patients, with mean baseline CD4 cell count at study entry of 32 cells/ microliter. Median duration of follow-up was 6 months.

The 6-month cumulative incidence of clinical disease progression or death was 17% for patients randomized to ritonavir compared to 34% for patients randomized to placebo. This difference in rates was statistically significant.

The 6-month cumulative mortality was 5.8% for patients randomized to ritonavir and 10.1% for patients randomized to placebo. This difference in rates was statistically significant.

In addition, analyses of mean CD4 cell count changes from baseline over the first 16 weeks of study for the first 211 patients enrolled (mean baseline CD4 cell count = 29 cells/microliter) showed that ritonavir was associated with larger increases in CD4 cell counts than was placebo. Compared to placebo, ritonavir also produced a greater mean decrease in HIV RNA levels from baseline.

Patients Without Prior Antiretroviral Therapy

In Study M94-245, 356 antiretroviral-naïve HIV-infected patients (mean baseline CD4 = 364 cells/microliter) were randomized to receive either ritonavir 600 mg twice daily, zidovudine 200 mg three times daily, or a combination of these drugs. In analyses of average CD4 cell count changes from baseline over the first 16 weeks of study, both ritonavir monotherapy and combination therapy produced greater mean increases in CD4 cell count than did zidovudine monotherapy. The CD4 cell count increases for ritonavir monotherapy were larger than the increases for combination therapy. Similarly, the mean decreases in HIV RNA level from baseline were larger with ritonavir monotherapy than with combination therapy or zidovudine monotherapy.

Combination Therapy with ritonavir, Zidovudine, and Zalcitabine in Antiretroviral- Naïve Patients

In Study M94-208, an open-label uncontrolled trial, 32 antiretroviral- naïve HIV-infected patients initially received ritonavir 600 mg twice daily monotherapy. Zidovudine 200 mg three times daily and zalcitabine 0.75 mg three times daily were added after 14 days of ritonavir monotherapy. Results of combination therapy for the first 20 weeks of this study show median increases in CD4

cell counts from baseline levels of 83 to 106 cells/microliter over the treatment period. Mean decreases from baseline in HIV RNA particle levels ranged from 1.69 to 1.92 logs.

14.3 Comparative Bioavailability Studies

COMPARATIVE BIOAVAILABILITY STUDIES

Fasting Study

A double blinded, randomized, two-treatment, two-sequence, two-period, crossover, single dose oral bioequivalence study of Auro-Ritonavir tablets, 100 mg (Auro Pharma Inc.) versus ^{Pr}Norvir[®] tablets, 100 mg (AbbVie Corporation) was conducted in 48 healthy, adult, human subjects under fasting conditions. A summary of the bioavailability data of 46 subjects who completed the study is presented in the following table.

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Ritonavir (1 x 100 mg) From measured data Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test*	Reference†	% Ratio of Geometric Means	90% Confidence Interval
AUC_{0→t} (ng.hr/mL)	7903.9 8721.5 (46.9)	9000.9 9830.5 (45.2)	87.8	82.2-93.8
AUC_{0→∞} (ng.hr/mL)	8150.6 9027.1 (48.5)	9235.6 10144.1 (47.5)	88.3	82.7 – 94.1
C_{max} (ng/mL)	977.1 1058.0 (39.6)	1164.8 1259.2 (39.5)	83.9	77.1-91.2
T_{max}‡ (hr)	3.7 (1.3-5.0)	3.0 (1.3-4.5)		
T_½§ (hr)	6.8 (22.9)	6.5 (23.6)		

*Auro-Ritonavir (Ritonavir) Tablets, 100 mg (Auro Pharma Inc.).

† ^{Pr}Norvir[®] (Ritonavir) Tablets, 100 mg (AbbVie Corporation) were purchased from Canada.

‡ Expressed as the median (range) only.

§ Expressed as arithmetic mean (% CV) only

Fed Study

A double blinded, randomized, two-treatment, two-sequence, two-period, cross-over, single-dose, oral bioequivalence study of Auro-Ritonavir tablets, 100 mg (Auro Pharma Inc.) versus PrNorvir® tablets, 100 mg (AbbVie Corporation) was conducted in 54 healthy, adult, human subjects under fed conditions. A summary of the bioavailability data of 50 subjects who completed the study is presented in the following table.

SUMMARY TABLE OF THE COMPARATIVE BIO-AVAILABILITY DATA

Ritonavir (1 x 100 mg) From measured data Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test*	Reference†	% Ratio of Geometric Means	90% Confidence Interval
AUC_{0→t} (ng.hr/mL)	4756.9 5288.8 (53.6)	5034.9 5679.8 (52.8)	94.5	87.5-102.0
AUC_{0→∞} (ng.hr/mL)	4989.4 5547.9 (54.1)	5287.2 5966.8 (53.1)	94.4	87.7- 101.6
C_{max} (ng/mL)	514.3 586.6 (59.9)	541.6 616.7 (58.8)	95.0	85.1-106.0
T_{max}‡ (hr)	4.5 (2.0-10.0)	4.5 (1.5-8.0)		
T_½§ (hr)	7.3 (18.5)	7.2 (19.9)		

*Auro-Ritonavir (Ritonavir) Tablets, 100 mg (Auro Pharma Inc.).

† PrNorvir® (Ritonavir) Tablets, 100 mg (AbbVie Corporation) were purchased from Canada.

‡ Expressed as the median (range) only.

§ Expressed as arithmetic mean (% CV) only.

15 MICROBIOLOGY

Resistance

HIV-1 isolates with reduced susceptibility to ritonavir have been selected in vitro. The clinical relevance of phenotypic and genotypic changes associated with ritonavir therapy has not been established (see **7 WARNINGS AND PRECAUTIONS** and **15 MICROBIOLOGY**). Genotypic analysis of these isolates showed mutations in the HIV protease gene at amino acid positions 84 (Ile to Val), 82 (Val to Phe), 71 (Ala to Val), and 46 (Met to Ile). Phenotypic (n = 18) and genotypic (n = 44) changes in HIV isolates from selected patients treated with ritonavir were monitored in Phase 1/2 trials over a period of 3 to 32 weeks. Mutations associated with the HIV viral protease in isolates obtained from 41 patients appeared to occur in a stepwise and ordered fashion; in sequence, these mutations were position 82 (Val to Ala/Phe), 54 (Ile to Val), 71 (Ala to Val/Thr), and 36 (Ile to Leu), followed by combinations of mutations at an additional 5 specific amino acid positions.

Of 18 patients for which both phenotypic and genotypic analysis were performed on free virus isolated from plasma, 12 showed reduced susceptibility to ritonavir in vitro. All 18 patients possessed one or more mutations in the viral protease gene. The 82 mutation appeared to be necessary but not sufficient to confer phenotypic resistance. Phenotypic resistance was defined as a ≥ 5 -fold decrease in viral sensitivity in vitro from baseline. The clinical relevance of phenotypic and genotypic changes associated with ritonavir therapy has not been established.

Cross-resistance to Other Antiretrovirals

Among protease inhibitors variable cross-resistance has been recognized (see **7 WARNINGS AND PRECAUTIONS** and **15 MICROBIOLOGY**). Serial HIV isolates obtained from 6 patients during ritonavir therapy showed a decrease in ritonavir susceptibility in vitro but did not demonstrate a concordant decrease in susceptibility to saquinavir in vitro when compared to matched baseline isolates. However, isolates from 2 of these patients demonstrated decreased susceptibility to indinavir in vitro (8-fold). Isolates from 5 patients were also tested for cross-resistance to amprenavir and nelfinavir; isolates from two patients had a decrease in susceptibility to nelfinavir (12- to 14-fold), and none to amprenavir. Cross-resistance between ritonavir and reverse transcriptase inhibitors is unlikely because of the different enzyme targets involved. One ZDV-resistant HIV isolate tested in vitro retained full susceptibility to ritonavir.

Cross-resistance between ritonavir and reverse transcriptase inhibitors is unlikely because of the different enzyme targets involved. One ZDV-resistant HIV isolate tested in vitro retained full susceptibility to ritonavir.

Antiviral Activity in vitro

The activity of ritonavir was assessed in vitro in acutely infected lymphoblastoid cell lines and in peripheral blood lymphocytes. The concentration of drug that inhibits 50% (EC₅₀) of viral replication ranged from 3.8 to 153 nM depending upon the HIV-1 isolate and the cells employed.

The average EC50 for low passage clinical isolates was 22 nM (n = 13). In MT4 cells, ritonavir demonstrated additive effects against HIV-1 in combination with either zidovudine (ZDV) or didanosine (ddI). Studies which measured cytotoxicity of ritonavir on several cell lines showed that > 20 microM was required to inhibit cellular growth by 50% resulting in an in vitro therapeutic index of at least 1000.

16 NON-CLINICAL TOXICOLOGY

The toxicology of ritonavir has been assessed in mice, rats, dogs and rabbits in studies ranging in duration from a single dose to 6 months of oral administration. All phases of the reproductive process have been evaluated for potential adverse effects, and a generally accepted battery of in vitro and in vivo mutagenicity studies has been conducted. The following section summarizes the findings from these studies. The most significant target organs in the toxicity studies have been the liver and retina. Retinal changes secondary to phospholipidosis were limited to rodents only and were considered not to pose any undue risk to humans. Dogs appeared to be less sensitive than the rodent to the hepatotoxic effects of ritonavir. Human clinical studies have not disclosed a high incidence of hepatic complications (see **8 ADVERSE REACTIONS**).

Pharmacodynamics

Ritonavir was administered orally to mice or rats at doses of 5 to 50 mg/kg to determine potential effects on various neuropharmacological endpoints. In mice, ritonavir had no meaningful effect on rotarod performance, ethanol-induced sleep time or pentobarbital-induced sleep time. In rats, no effect was observed on spontaneous motor activity or rotarod performance.

Ritonavir produced no pharmacologically significant effects on heart rate or blood pressure when administered orally to unanesthetized rats at doses of 20 or 50 mg/kg. The compound was also infused intravenously in a vehicle consisting of 20% ethanol and 15% propylene glycol in 5% dextrose water to pentobarbital-anesthetized dogs instrumented to measure various cardiovascular parameters.

Mean peak plasma levels of ritonavir were as high as 15.11 mcg/mL. Although the vehicle itself produced hemodynamic changes consistent with cardiac depression, ritonavir produced no consistent additional effects on systemic or pulmonary pressures or resistance, central venous pressure, cardiac output, left ventricular dP/dt or end-diastolic pressure.

Ritonavir had no effect on isolated guinea pig ileum basal tone or on carbachol-induced contractions.

Acute Toxicity

Ritonavir has a low order of acute toxicity in rodents by oral route but is more toxic when given

intravenously. The difference is probably due to the fact that the acute toxicity produced by ritonavir is more related to plasma C_{max} than AUC values, and C_{max} is most likely considerably higher following intravenous injection. When given orally in a vehicle of propylene glycol and ethyl alcohol (95:5, v/v) containing 2 molar equivalents of p-toluene sulfonic acid monohydrate, the median lethal dose (LD50) generally exceeds the limited dose of 2500 mg/kg for both mice and rats. Toxic signs for both species consisted of decreased activity, ataxia, dyspnea, squinting, prostration, and tremors.

When administered intravenously, the approximately lethal dose (ALD) ranged from 35 to 80 mg/kg for both species. Signs of toxicity included decreased activity, ataxia, dyspnea, exophthalmos, and clonic convulsions.

Sub-chronic Toxicity

Rat

Ritonavir has been studied in rats at study durations for 1-month (0, 15, 50 and 150/100 mg/kg/day), 13-weeks (0, 25, 75, and 175/125 mg/kg/day) and 6-months (0, 25, 75, and 175/125 mg/kg/day). Consistent findings across all studies included treatment-related clinical signs consisting of decreased activity, emaciation, hunched posture, weakness, and rough hair coat along with some indications of ataxia, lower body weight and food consumption at higher dosages. Target organs of toxicity were liver, eye (retina), kidney and thyroid.

Hepatic changes include multinucleated hepatocytes, single cell necrosis, histiocytic granulomas and chronic pericholangitis. Changes in laboratory parameters consistent with these findings were observed in serum for ALT, AST, GGT, ALP, total bilirubin, and cholesterol.

Retinal changes included observation of pale choroidal vasculature, with hypertrophy and cytoplasmic granularity in the retinal pigment epithelium, with reduced or absent photoreceptor outer segments. Electroretinograms (ERGs) revealed decreases in A- and B-wave amplitudes, with primary findings associated with rods. Recovery was not observed following treatment discontinuation.

Mild epithelial hypertrophy in the thyroid gland was associated with increased TSH and lower T4. Kidney changes were consisted of tubular degeneration and were only observed in the 6-month study.

The no-toxic effect dosage was considered to be 15 mg/kg/day and corresponded to systemic exposure of 3.6 to 4.7 mcg.h/mL in male rats and 5.3 to 8.9 mcg.h/mL in female rats (approximately 1/25th of the expected human exposure of 150 mcg.h/mL from a dose of 600 mg twice daily).

Dog

Ritonavir has been studied in dogs at study durations for 1-month (0, 10, 50 and 200 mg/kg/day), 13-weeks (0, 10, 50, and 200/100 mg/kg/day) and 6-months (0, 10, 50 and 125 mg/kg/day). Consistent findings across all studies included treatment-related clinical signs consisting of emesis and abnormal stool/diarrhea; at higher dosages decreased activity, ataxia, weakness, tremor, and posture difficulties were observed along with decreased body weight and food intake. Target organs of toxicity were liver and thymus. Due to pronounced clinical adversity and moribundity the high dosage was reduced from 200 to 100 mg/kg/day in the 13- week study.

Hepatic changes included histopathological findings of hydropic degeneration, with pericholangitis, biliary hyperplasia, fibrosis becoming evident as the dose duration increased. Associated changes in serum markers included ALT, ALLP, GGT, and bile acids.

Decreased thymic weight and atrophy were observed at the highest dosages.

The no-toxic effect dosage was dependent on the test formulation used and ranged from 10 to 50 mg/kg/day that corresponded to systemic exposure of 18 to 25 mcg.h/mL (approximately one-seventh of the expected human exposure of 150 mcg.h/mL). However, it is important to note that histopathological changes in liver were only observed in a single female dog at the highest dosage (125 mg/kg/day) at a plasma drug exposure of 482 mcg.h/mL.

Carcinogenicity

Carcinogenicity studies with ritonavir have been conducted in mice and rats. In male mice, at dosage levels of 50, 100, or 200 mg/kg/day, there was a dose dependent increase in the incidence of both adenomas and combined adenomas and carcinomas in the liver. Based on the drug exposure (AUC) measurements, the exposure at the high dosage was approximately 0.3-fold for males that of exposure in humans with the recommended therapeutic dose (600 mg twice daily). There were no carcinogenic effects seen in females at the dosages tested. The exposure at the high dosage was approximately 0.6-fold for the females that of the exposure in humans. In rats dosed at levels of 7, 15 or 30 mg/kg/day there were no carcinogenic effects. In this study the exposure at the high dose was approximately 5% that of the exposure in humans with the 600 mg twice daily regimen. Based on the exposures achieved in the animal studies, the significance of the observed effects is not known.

Mutagenicity

Ritonavir was not found to be mutagenic or clastogenic in a battery of in vitro and in vivo assays including the Ames bacterial reverse mutation assay using *S. Typhimurium* and *E. coli*, the mouse lymphoma assay, the mouse micronucleus test, and chromosomal aberration assays in human lymphocytes.

Reproductive and Developmental Toxicology

Fertility and General Reproductive Performance

Rats

Ritonavir was administered orally by gavage to female rats at dosages of 0, 20, 40, and 75 mg/kg/day beginning at 14 days prior to mating with males that were treated at dosages of 0, 20, 40, and 125 mg/kg/day beginning at 28 days prior to mating. The treatment in female rats was continued through mating until gestation Day 9. The group mean plasma AUC values for males near the end of the pre-mating period were 8.2, 19.7 and 61.0 mcg·h/mL, respectively, for the 20, 40, and 125 mg/kg/day treatment groups. The corresponding values for females were 14.6, 33.1 and 90.5 mcg·h/mL, respectively, for the 20, 40 and 75 mg/kg/day treatment groups. There were no treatment-related deaths in the study. Maternal toxicity consisted of adverse clinical signs and decreases in mean body weights and food intake in the mid and high dosage groups.

There were no treatment-related effects on the estrous cycle or male and female reproductive indices. Maternal survival and pregnancy status of the ritonavir-treated groups were also comparable to the controls. No treatment-related effects were seen in the number of corpora lutea, implantation sites, viable and nonviable embryos. There were no increases in the incidence of preimplantation and postimplantation losses. The no-toxic-effect level for systemic toxicity in F0 generation rats was 20 mg/kg/day. However, there were no adverse effects on male or female reproduction or early embryonic development up to the highest dosage (125/75 mg/kg/day) tested.

Developmental Toxicity

Rats

Ritonavir was administered orally to mated female rats at dosages of 0, 15, 35, and 75 mg/kg/day from Gestation Day 6 to 17. Three high dosage rats were euthanized in moribund condition during the study. The group mean plasma AUC values on Gestation Day 16 were 17.3, 34.3 and 45.2 mcg·h/mL at dosages of 15, 35 and 75 mg/kg/day, respectively. Decreased activity, emaciation, dehydration, rough coat and/or matted coat, hunched posture, tremors, and noisy respiration were observed in rats at the high dosage level. Marked decreases in body weights and food consumption were evident in the high dosage group. Reduction in food consumption accompanied by a reduction in body weight gain was also noted for the mid dosage group during Gestation Days 6 to 9. No effects were found in the number of corpora lutea or implantation sites. Developmental toxicity in the high dosage group was characterized by increased postimplantation loss, decreased fetal body weights, and an increased incidence of ossification delays and developmental variations (enlarged fontanelles, cryptorchidism, and wavy ribs). Developmental toxicity at the 35 mg/kg/day dosage level was characterized by a slight increase in cryptorchidism. No treatment-related malformations were observed in this study.

Developmental toxicity occurred only at maternally toxic dosages. The no-effect level for maternal and developmental toxicity was 15 mg/kg/day corresponding to a systemic exposure of

17.3 mcg·h/mL.

Rabbits

Ritonavir was administered to mated female rabbits by oral gavage at dosages of 0, 25, 50, and 110 mg/kg/day from Gestation Day 6 to 19. The group mean plasma AUC values on Gestation Day 20 were 1.30 and 28.55 mcg·h/mL at dosages of 25 and 50 mg/kg/day, respectively. Plasma AUC values were not calculated for the 110 mg/kg/day group because plasma samples were obtained from the 3 surviving rabbits at only 2 time points. Four deaths in rabbits given 110 mg/kg/day were considered to be possibly drug-related. There was an increased incidence of decreased defecation and soft stool in all drug-treated groups. The observation of no stool was noted in mid and high dosage groups; rales and mucoid stool occurred only at the high dosage. Marked decreases in body weights, body weight gain and food consumption were noted in the high dosage group. Developmental toxicity was evident at the high dosage level with 4 whole litter resorptions and in surviving litters a significant increase in postimplantation losses, decreased litter size and decreased uterine and fetal weights. There were no drug-related fetal malformations in this study.

The no-observable-effect level was 50 mg/kg/day with respect to maternal and developmental toxicity.

Special Toxicology Studies

Dietary administration of ritonavir was provided to mice and rats for 13-weeks in preparation for 2-year carcinogenicity studies in these species. Dosages were 0, 200, 400, 600, and 1000 mg/kg/day for mice and 0, 50, 100, 160, and 200 mg/kg/day for male rats and 0, 30, 75, 125, and 175 mg/kg/day for female rats. In both species target organ toxicity was similar to that noted in the 3-month rat study using oral gavage administration, with target organ toxicities in liver, eye (retina), and thyroid (rat only). Systemic plasma exposure (AUC) associated with target organ toxicity was similar to plasma exposures in the 3-month study in rats.

Ritonavir was evaluated for the potential to produce delayed contact hypersensitivity in guinea pigs. The Maximization Method was used in this study and the data generated indicated that ritonavir did not induce delayed contact hypersensitivity in guinea pigs.

Peri-/Postnatal Toxicity

Rats

Mated female rats were administered ritonavir orally at dosages of 0, 15, 35, or 60 mg/kg/day beginning on Gestation Day (GD) 6. Treatment continued throughout gestation, parturition, and lactation; the final dosage was given on Postpartum Day (PD) 20. Plasma drug levels were not determined in this study. No deaths or treatment-related clinical signs were observed among the F0 dams. Dams in the 60 mg/kg/day group gained less weight and consumed less food during GD

6 to 9. Gestation length, litter size at birth, and F1 pup growth and survival were unaffected. No effects on the time of appearance of developmental landmarks or learning as measured by a passive avoidance test were evident. The ontogeny of various reflexes was unaffected. The reproductive competence of the F1 generation was unaffected. Therefore, the no-observed-effect level for developmental toxicity was considered to be 60 mg/kg/day, the highest dosage tested.

17 SUPPORTING PRODUCT MONOGRAPHS

1. NORVIR®, Tablets, 100 mg, Submission Control Number: 249539, Product Monograph, AbbVie Corporation, Date of revision: July 05, 2021.

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr **Auro-Ritonavir**

Ritonavir Tablets

Read this carefully before you start taking **Auro-Ritonavir** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Auro-Ritonavir**.

When taking **Auro-Ritonavir** with other protease inhibitors, consult the PART III of that protease inhibitor's Product Monograph.

Serious Warnings and Precautions

Auro-Ritonavir can cause **pancreatitis** (inflammation of the pancreas).

Tell your doctor if you develop symptoms, such as:

- **abdominal pain**
- **nausea**
- **vomiting**

These may be signs of **pancreatitis**. Your doctor must decide if these are related to pancreatitis and what to do about them.

Auro-Ritonavir may react with certain drugs and cause serious and life-threatening side effects. Read the “Do not use Auro-Ritonavir if” and “The following may interact with Auro-Ritonavir” sections, below, very carefully.

What is Auro-Ritonavir used for?

- the treatment of HIV (Human Immunodeficiency Virus) Infection
- HIV is the virus that causes Acquired Human Immunodeficiency Syndrome (AIDS)
- it is used in adults and children 2 – 16 years of age
- it is used along other medicines to treat HIV infection

How does Auro-Ritonavir work?

- Auro-Ritonavir works by stopping the HIV virus from multiplying. This will help lower the amount of HIV in your body and keep it at a low level.
- Auro-Ritonavir is not a cure for HIV infection or AIDS. You can still get infections or other

serious illnesses associated with HIV infection or AIDS.

- Auro-Ritonavir does not reduce the risk of passing HIV to others with sexual contact or blood contamination. You should use appropriate precautions, such as practicing safe sex and not reusing or sharing needles.

What are the ingredients in Auro-Ritonavir?

Medicinal ingredient: ritonavir

Non-medicinal ingredients: The film coat, Aquarius Prime BAP 118010 White contains: Hypromellose 2910, Titanium Dioxide, Talc, Polyethylene glycol and Polysorbate.

The tablet core contains: Calcium Hydrogen Phosphate Anhydrous, Calcium Hydrogen Phosphate Dihydrate, Copovidone, Maize starch, Mannitol, Microcrystalline Cellulose, Silicified Microcrystalline Cellulose (Prosolv SMCC 50), Silicified Microcrystalline Cellulose (Prosolv SMCC 90), Powdered Cellulose, Sodium Stearyl Fumarate and Sorbitan Laurate.

Auro-Ritonavir comes in the following dosage forms:

Auro-Ritonavir is available as film-coated tablets containing 100 mg ritonavir

Do not use Auro-Ritonavir if:

- you are allergic to ritonavir or to any of the ingredients in Auro-Ritonavir.
- Do not use Auro-Ritonavir if you are currently taking any of the following medicines. Taking Auro-Ritonavir with these can cause serious problems and death:
- alfuzosin, used to treat high blood pressure
 - amiodarone, bepridil, dronedarone, flecainide, propafenone, quinidine, used to treat irregular heart beats
 - apalutamide, used for prostate cancer
 - astemizole or terfenadine, used to relieve allergy symptoms
 - cisapride, used to relieve certain stomach problems
 - colchicine, when used in patients with kidney and/or liver problems, used to treat gout
 - ergotamine, dihydroergotamine (used to treat headaches), ergonovine, methylergonovine (used after labour and delivery)
 - fusidic acid, used as an antibiotic
 - lovastatin, lomitapide or simvastatin used to lower blood cholesterol
 - lurasidone, pimozide used to treat mental health problems
 - neratinib, used to treat breast cancer
 - ranolazine, used to treat chronic angina (chest pain)
 - rifampin and saquinavir, used to treat tuberculosis, should not be used together with ritonavir
 - rivaroxaban, used as an anticoagulant
 - salmeterol, used for asthma and chronic obstructive pulmonary disease

- St. John's Wort (*Hypericum perforatum*), an herbal product used to treat depression
- triazolam and midazolam (oral or injected), used to relieve anxiety and/or trouble sleeping
- PDE5 inhibitors vardenafil, used to treat erectile dysfunction, or sildenafil, used for the treatment of pulmonary arterial hypertension (PAH)
- voriconazole, used as an antifungal
- venetoclax during the dose initiation and during the ramp-up phase, used to treat chronic lymphocytic leukemia

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Auro-Ritonavir. Talk about any health conditions or problems you may have, including if you:

- have liver problems.
- are infected with hepatitis B or hepatitis C. If you have liver disease, such as hepatitis B and hepatitis C, taking Auro-Ritonavir may worsen your liver disease.
- have diabetes or symptoms, such as frequent urination and/or increase in thirst.
- have hemophilia, since taking Auro-Ritonavir can increase bleeding in these patients.
- have heart disease or heart condition, including conditions of Congenital Long QT Syndrome.
- have been told you have high triglyceride levels in your blood.
- have had a condition called pancreatitis in the past.

Other warnings you should know about:

Pregnancy

Tell your doctor if you are pregnant or planning to become pregnant. It is not known if Auro-Ritonavir can harm your unborn baby. Tell your doctor if you become pregnant while you are taking Auro-Ritonavir.

Pregnancy Registry

There is a pregnancy registry for women who take antiretroviral medicines while they are pregnant. The purpose of this registry is to collect information about the health of you and your baby. If you do become pregnant while taking Auro-Ritonavir, talk to your doctor about taking part in this registry.

Breastfeeding

You should not breastfeed if you are taking Auro-Ritonavir. You should also not breastfeed a baby if you are infected with HIV. This is because you can pass HIV to your baby.

Severe Liver Problems

Severe liver problems, including deaths, have been reported in those using Auro-Ritonavir. This has often occurred in those with advanced HIV disease, other liver disease or those taking

many medications. Symptoms of serious liver problems include yellow skin and whites of eyes, nausea, tiredness, loss of appetite, fever, skin rash, pain in the upper abdomen, pale stools, and dark-coloured urine. Talk to your doctor if you get any of these symptoms.

Contraception

If you are taking oral contraceptives (“the pill”) or the contraceptive patch (i.e., ethinyl estradiol) to prevent pregnancy, you should use a different type of contraception since Auro-Ritonavir may reduce the effectiveness of oral or patch contraceptives.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements, or alternative medicines.

The following medicines should only be used together with Auro-Ritonavir if advised by your physician.

The following may interact with Auro-Ritonavir:

- medicines used to treat erectile dysfunction, such as tadalafil
- medicines used to treat pulmonary arterial hypertension, such as bosentan or tadalafil
- medicines used to lower blood cholesterol, such as atorvastatin and rosuvastatin
- some medicines affecting the immune system, such as cyclosporin, sirolimus and tacrolimus
- some medicines used to treat seasonal allergies and ear and eye infections, such as budesonide, dexamethasone, fluticasone propionate, prednisone, and triamcinolone
- medicines used to treat AIDS and related infections, such as amprenavir, indinavir, nelfinavir, saquinavir, didanosine, rifabutin, tipranavir, delavirdine, atazanavir, maraviroc, fosamprenavir, raltegravir, tenofovir and darunavir
- medicines used to treat depression, such as trazodone, desipramine and bupropion
- certain heart medicines, such as calcium channel antagonists including diltiazem, nifedipine and verapamil
- medicines used to correct heart rhythm, such as systemic lidocaine and digoxin
- antifungals, such as ketoconazole and itraconazole
- morphine-like medicines used to treat severe pain such as methadone and meperidine

- anticonvulsants, such as carbamazepine, phenytoin, and phenobarbital
- anticoagulants, such as warfarin
- certain antibiotics, such as rifabutin and clarithromycin
- antibiotics used in the treatment of tuberculosis, such as Rifampin
- bronchodilators used to treat asthma, such as theophylline
- medicines used to treat cancer, such as abemaciclib, dasatinib, encorafenib, ibrutinib, nilotinib, vincristine and vinblastine
- medicines used for low blood platelet count, such as fostamatinib
- some heart rhythm drugs, such as mexiletine and disopyramide
- some anticonvulsants, such as clonazepam, divalproex, lamotrigine and ethosuximide
- some narcotic analgesics, such as fentanyl in all forms, tramadol and propoxyphene
- quetiapine used to treat schizophrenia, bipolar disorder and major depressive disorder
- medicines used to treat hepatitis C, such as simeprevir, glecaprevir/pibrentasvir or ombitasvir, paritaprevir and ritonavir with or without dasabuvir
- some sedatives or medicines to treat anxiety, such as buspirone, clorazepate, diazepam, flurazepam and zolpidem
- stimulants, such as methamphetamine
- medicines used to treat pain associated with endometriosis, such as elagolix

How to take Auro-Ritonavir:

- Take Auro-Ritonavir exactly as your doctor tells you to.
- Do not change your dose or stop taking Auro-Ritonavir without talking to your doctor.
- You must stay under your doctor's care when taking Auro-Ritonavir.
- Swallow the Auro-Ritonavir tablets whole. Do not chew, break, or crush tablets.
- You should take Auro-Ritonavir tablets with food.

Usual dose:

- Your doctor will tell you how much Auro-Ritonavir you should take and when you should take it.
- The usual dose for adults is six 100 mg tablets twice a day.

Overdose:

If you think you, or a person you are caring for, have taken too much Auro-Ritonavir, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed dose:

If you missed a dose of this medication, take it as soon as you remember. But if it is almost time for your next dose, skip the missed dose and continue with your next scheduled dose. Go back to the regular dosing schedule. Do not take 2 doses at the same time.

What are possible side effects from using Auro-Ritonavir?

These are not all the possible side effects you may feel when taking Auro-Ritonavir. If you experience any side effects not listed here, contact your healthcare professional.

Side effects may include:

- Changes in taste
- Diarrhea
- Dizziness
- Feeling weak or tired
- Headache
- Loss of appetite
- Tingling feeling or numbness in hands, feet or around the lips
- Some patients have large increases in triglycerides and cholesterol (forms of fat that are found in your blood)

Changes to your immune system (Immune Reconstitution Inflammatory Syndrome) can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time.

Autoimmune disorders (when the immune system attacks healthy body tissue) may also occur after you start taking medicines for HIV infection. Examples of this include: Grave's disease

(which affects the thyroid gland), Guillain-Barré syndrome (which affects the nervous system), polymyositis (which affects the muscles), or autoimmune hepatitis (which affects the liver). Autoimmune disorders may occur many months after the start of treatment. Look for any other symptoms such as:

- high temperature (fever), redness, rash or swelling
- fatigue
- joint or muscle pain
- numbness or weakness beginning in the hands and feet and moving up towards the trunk of the body
- palpitations (chest pain) or rapid heart rate
- yellowing of the skin or eyes

If you notice these or any symptoms of inflammation or infection, tell your doctor immediately.

Your doctor may monitor blood levels of fats (lipids), cholesterol and glucose before and during Auro-Ritonavir treatment.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
UNCOMMON			
Chest Pain		√	
Diabetes or hyperglycemia (high blood sugar): increased thirst, frequent urination, dry skin, headache, blurred vision, and fatigue		√	
Pancreatitis (inflammation of the pancreas): abdominal pain, nausea, and vomiting		√	
Severe liver Problems: yellow skin and whites of eyes, nausea, tiredness, loss of appetite, fever, skin rash, pain in the upper abdomen, pale stools, and dark- coloured urine		√	
Stevens-Johnson syndrome (SJS) (severe skin rash): redness, blistering and/or peeling of the skin and/or inside of the lips, eyes, mouth, nasal passages or genitals, accompanied by fever, chills, headache, cough, body aches or swelling			√

Toxic Epidermal Necrolysis (TEN) (severe skin reaction): redness, blistering and/or peeling of large areas of the skin			√
---	--	--	---

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

- Store between 15 and 30°C. It is recommended that the product be stored and dispensed in the original container.
- Exposure of the product to high humidity outside the original container is not recommended.
- Do not use after the expiry date on the package. Keep out of reach and sight of children.

If you want more information about Auro-Ritonavir:

- Talk to your healthcare professionals
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website <http://www.auropharma.ca>, or by calling 1-855-648-6681.

This leaflet was prepared by Auro Pharma Inc.

Last Revised: December 22, 2021.